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ABSTRACT
Parkinson’s disease (PD) and Primary Sclerosing Cholangitis (PSC) are idiopathic diseases 
for which an external agent, e.g. a microorganism, has been hypothesised as being causally 
related to the condition or as having a potential role in disease progression. In the present 
work, we present evidence that gut and oral microbiota, but not nasal, diff er between con-
trols and PD patients, and that, regardless of hypothetical causal relationships, some of these 
changes show potential for use as biomarkers for diagnostic purposes. Although none of 
our studies are designed to investigate causality, we nevertheless fi nd no suggestion that the 
bile microbiota is aetiologically related to PSC. On the other hand, our results suggest that 
Streptococcus may contribute to disease progression. All the studies are unifi ed by the same 
methodology, consisting on case-control studies using high-throughput amplicon sequenc-
ing of the bacterial 16S rRNA gene, followed by bioinformatic processing of the raw data, and 
fi nally by statistical analysis.
ABSTRAKTI
Parkinsonin tauti (PD) ja primaarinen sklerosoiva kolangiitti (PSC) ovat idiopaattisia sai-
rauksia joiden synnyn tai etenemisen on epäilty liittyvän ulkopuoliseen tekijään, esimer-
kiksi johonkin mikro-organismiin. Tässä tutkielmassa esittämämme löydökset osoittavat, 
että suoliston ja suun mikrobit poikkeavat Parkinsonin tautia sairastavien potilaiden sekä 
kontrollihenkilöiden välillä, mutta nenän mikrobit eivät. Riippumatta siitä, liittyvätkö löy-
detyt erot taudin etenemiseen, osa niistä voisi mahdollisesti toimia biomarkkereina tau-
tidiagnostiikassa. Vaikka tutkimuksiamme ei ole varsinaisesti suunniteltu selvittämään 
syy-seuraussuhteita, emme löydä viitteitä siitä, että sapen mikrobit vaikuttaisivat PSC:n 
syntyyn. Toisaalta tulostemme perusteella näyttäisi siltä, että  Streptococcus  saattaa edistää 
taudin pahenemista. Kaikkia tutkimuksia yhdistää sama metodologia: ne ovat tapaus-
verrokkitutkimuksia, jotka perustuvat bakteerien 16S rRNA:ta koodaavan geenin suuren 
kapasiteetin amplikonisekvensointiin jota seuraa sekvenssitiedon bioinformaattinen käsittely 
ja lopuksi tilastollinen analyysi.
Kindly translated to Finnish by Velma Aho.
ABBREVIATIONS
BMAA  β-N-methylamino-L-alanine
CNS  central nervous system
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11.  INTRODUCTION
1.1.  A Brief Overview of the Human Microbiome in Health & Disease
Th e human microbiome refers to the microbial communities found in and on the human body. 
Th ese communities are composed of bacteria, archaea, and microbial eukaryotes, as well as human 
and microbial viruses (Aho et al. 2015). Th e term microbiome was coined by Joshua Lederberg 
in 2001 in the context of human microbial communities, and was defi ned as “the ecological 
community of commensal, symbiotic, and pathogenic microorganisms that literally share our 
body space and have been all but ignored as determinants of health and disease” (Lederberg 
& McCray 2001). Th e term was later adopted by microbial ecologists as referring to microbial 
communities found in and on any kind of environment, and the term also took a more inclusive 
meaning by taking into account the physical environment itself within the defi nition, thus better 
refl ecting the biome concept in theoretical ecology (Aho et al. 2015). Th e term microbiota has a 
similar meaning but ignores the physical environment, thus referring strictly to the collection of 
organisms in a given environment. Th ese two terms are oft en used as synonyms both colloquially 
and in the literature but in practice the intended meaning is clearly understood from context. 
Much confusion remains in the literature regarding the terms metagenomics and metagenome. 
A metagenome is the collection of all genetic material, ideally assembled into complete genomes, 
found in a given environment. In practice, however, obtaining complete genomes from most 
microbial environments is still technically problematic except by using very deep sequencing 
in the most extreme, low-energy, and/or highly oligotrophic environments. For the most part, 
the term is used specifi cally in the context of microbial ecology but conceptually can refer also 
to macro-organisms (e.g. Bourlat et al. 2013). Metagenomics, on the other hand, is a body of 
techniques for obtaining information on metagenomes, of which shotgun metagenomics is an 
example. As in genomics, metagenomics has the advantage, unlike 16S rRNA gene surveys, of 
providing direct evidence for the genetic make-up of microbial communities. Th is means that it 
is possible to infer functional information about the organisms, for example the distribution of 
metabolic pathways in the community. However, metagenomics does not provide information 
on gene expression, and thus we can only obtain information on the functional potential of the 
community. A complementary approach is metatranscriptomics, which, in an analogous way to 
transcriptomics, can provide data on the activities of the communities at the time the samples 
are taken. Metatranscriptomics relies on RNA sequencing and analysis of gene expression. Th e 
studies presented in this thesis (I, II, III) are, strictly speaking, not metagenomics-based. Instead, 
they are better labelled as phylogenetic marker gene surveys using high-throughput 16S rRNA 
gene amplicon sequencing technology. Th us, no direct information on the functional capabilities 
of the communities can be obtained, except indirectly through taxonomic identifi cation of the 
sequences followed by extrapolation.
Estimations of the quantity of microorganisms present in the human body at any given 
time has led to the suggestion that the number of bacterial cells, specifi cally, may exceed our 
own by an order of magnitude (Savage 1977, Turnbaugh et al. 2007). Th ese estimations have 
been criticized on the basis that microbiome-related interpersonal variation is very high and that 
estimations of the number of human cells themselves are surprisingly unreliable, ranging from 
5x1012 to 7x1016 cells, depending on the author (Bianconi et al. 2013, Torres 2014). Th e number 
of diff erent protein-coding genes present in these communities, even by conservative estimates, 
far exceeds the estimated number of protein-coding genes in humans: ~3.3 to ~9.9 million 
bacterial genes vs ~19.000 human genes (Qin et al. 2010, Ezkurdia et al. 2014, Li et al. 2014). Th e 
ecological relationships of these microbiota with the human host vary between commensalism, 
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2mutualism, amensalism, and parasitism, with any given microorganism potentially being 
able to shift  its relationship with its host depending on present conditions and opportunities. 
For example, opportunistic pathogens represent a type of amphibiosis (Rosebury 1962), and 
consist of microorganisms that are commonly present in healthy individuals in a state of non-
pathogenicity, usually in low abundances, and that may become pathogenic due to e.g. abnormal 
growth promoted by microbial community disruption, access to normally inaccessible tissues, a 
compromised immune system, etc. It is still common to refer to the non-pathogenic microbiota 
simply as commensals in the literature, but this is an ecological oversimplifi cation.
Ilya Metchnikoff , whose work laid the foundation for the modern fi eld of immunology 
together with Paul Erlich (Kaufmann 2008), was the fi rst to actively promote the essential role of 
microbiota in the general health of the human host (Metchnikoff  1908, Bhattacharjee & Lukiw 
2013), thus joining the ranks of other contemporary visionaries such as Vladimir Vernadsky and 
Sergei Winogradsky in his holistic approach to microbiology. Since then, a voluminous body 
of work has been produced on the relationship between the human microbiome and health 
& disease in general (see e.g. Shreiner et al. 2015, Lynch & Pedersen 2016, Young 2017 for an 
overview). For an historical perspective on microbial endocrinology and the microbiota-gut-
brain axis in particular, see the extensive three-part literature review by Bested et al. (2013a), 
Bested et al. (2013b), and Bested et al. (2013c), and for an introduction to the subject see e.g. Lyte 
& Cryan (2014) and Dinan & Cryan (2017b).
Th e introduction of high-throughput DNA sequencing technology has enabled culture-
independent methods to make major strides in the detection and characterization of bacteria 
and other microorganisms, including in locations of the human body that have previously been 
considered sterile environments except under unhealthy states, e.g. in the lower respiratory 
tract of healthy individuals (Morris et al. 2013, Segal et al. 2013). Th ere are many challenges in 
16S rRNA gene survey studies, in particular in relation to the inability to diff erentiate between 
free DNA and living cells, the low biomass of the starting material, and possible contamination 
either during sampling or due to contaminated reagents for sample processing (Pezzulo et al. 
2013, Lazarevic et al. 2014, Salter et al. 2014, Aho et al. 2015). To a greater or lesser degree, 
these are issues that have the potential to aff ect any 16S rRNA gene-based study, and need to be 
taken into account during the planning of sampling methodology, DNA extraction and library 
construction, and sequence data processing.
Pyrosequencing was commercially developed in its most well-known incarnation by 
the company 454 Life Sciences, founded in 2000 by Jonathan Rothberg. Released in 2005, the 
original instrument’s name was Genome Sequencer GS20, and it catapulted high-throughput 
(pyro)sequencing into the limelight. Th e company was eventually bought by Roche Diagnostics 
in 2007, and by mid 2016 Roche discontinued the 454 platform. It was during 2012-2013 that 
we used the 454 platform to sequence the stool samples that would provide the data for Study I. 
454-pyrosequencing used a sequencing-by-synthesis (SBS) approach, meaning that sequencing 
of DNA relied on the enzymatic activity of a DNA polymerase. SBS is still by a large margin the 
most common technology for DNA sequencing. Th e 454 platform used emulsion polymerase 
chain reaction (PCR) for amplifi cation of DNA fragments on the surface of beads. Th ese would 
then be moved to a well (acting as a micro-reactor) on the surface of a picotiter plate, where the 
actual SBS process would occur. Incorporation of a nucleotide would release a pyrophosphate 
that would be converted to ATP. Luciferase would then use the released ATP to oxidize luciferin, 
thus producing a light signal detectable by a camera. In its halcyon days, 454 technology would 
allow read lengths of circa 800-1000 base-pairs with FLX+ chemistry or 400-500 base-pairs 
with Titanium chemistry. We used the latter for amplicons in Study I. 454 would produce circa 
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3one million sequences per run with both chemistries, making it a veritable workhorse for 16S 
rRNA gene amplicon sequencing studies in microbial ecology (Margulies et al. 2005, Rothberg 
& Leamon 2008, Goodwin et al. 2016). Th e 454 platform was eventually supplanted, within 
the context of microbial ecology, by the MiSeq platform from Illumina. Th is company was 
founded in 1998 by David Walt, and it acquired the company Solexa in 2007, which had also 
been founded in 1998. Solexa released its Genome Analyser DNA sequencing platform in 2006, 
which was then further optimised and re-released by Illumina in 2009. Th e MiSeq platform 
itself was released in 2011 and, like 454, it’s also based on SBS technology. It uses bridge PCR 
amplifi cation of DNA fragments anchored to the surface of a fl ow-cell, forming clone clusters 
or “colonies”, and detection of fl uorescence for determination of nucleotide incorporation. We 
used MiSeq in 2014-2015 to sequence the samples for studies II and III, since our laboratory had 
by now acquired the platform. Th e MiSeq platform in its present form allows for the sequencing 
of circa 25 million reads per run (50 million paired-end), with maximum read lengths up to 
300 + 300 base-pairs pair-ended with v3 chemistry. It’s read lengths are shorter than those from 
454, but this can be compensated by using paired-end reads (sequencing matched forward and 
reverse complements) if sequencing longer amplicons is desired (e.g. V1-V3 regions of the 16S 
gene, as in the studies presented in this thesis; Goodwin et al. 2016). Th e main advantage of the 
MiSeq platform over the Roche 454 is that it produces substantially more reads per run. Th is 
enables samples to be sequenced more deeply, and thus provide a more representative view of 
community composition, including rarer taxa.
A growing number of studies are investigating the human microbiome not only in healthy 
individuals but also in relation to several medical conditions. A full survey of the literature 
is beyond the scope of the present introduction, but examples such as cystic fi brosis (Surette 
2014, McGuigan & Callaghan 2015, Bacci et al. 2016, Feigelman et al. 2017), chronic obstructive 
pulmonary disease (Sze et al. 2014), asthma (Beigelman et al. 2014), autism (De Angelis et al. 
2013, Kang et al. 2013, Krajmalnik-Brown et al. 2015, Son et al. 2015), Alzheimer’s disease 
(Harach et al. 2017), Parkinson’s disease (Hasegawa et al. 2015, Keshavarzian et al. 2015, Unger et 
al. 2016, Hill-Burns et al. 2017), arthritis (Scher et al. 2013, Chen et al. 2016a), colon cancer (Ou 
et al. 2013), diabetes (Kostic et al. 2015), and primary sclerosing cholangitis (Kummen et al. 2016, 
Sabino et al. 2016, Torres et al. 2016), illustrate well the importance that human microbiome 
studies have achieved in medical science during the last decade. It is in the context of this body of 
work that the three studies presented in this thesis were conducted.
1.2. The Ra? onale for Microbiome Studies in Parkinson’s Disease
Parkinsons’s disease (PD) is an idiopathic condition that manifests itself mostly through impaired 
motor function, gastrointestinal, olfactory, and oral disturbances, as well as behavioural problems 
(Sveinbjornsdottir 2016). Th e early classical symptoms consist of muscular rigidity, slow 
movements, resting tremors, changes in gait, and postural instability. Later symptoms include 
abnormal behaviour, depression, and dementia. However, there is a range of symptoms that may 
manifest at an earlier stage, in many cases preceding formal diagnosis of the disease by ~10 years 
(Schrag et al. 2015). Chiefl y among these is gastrointestinal dysfunction, which is present in 80% 
of the cases and is mostly represented by slow gastrointestinal transit (constipation), worsening 
as the disease progresses. Th e latter condition may also predispose patients to small intestinal 
bacterial overgrowth (SIBO; Fasano et al. 2013, Niu et al. 2016).
PD is a progressive neurodegenerative disorder associated with aging, and is the second 
most common disease in this class at the global level (de Lau & Breteler 2006, Pringsheim et al. 
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42014). Th ere are genetic factors involved in PD, with 28 distinct chromosomal regions possibly 
being related to the disease. In these, six genes have been identifi ed containing mutations that are 
consensually thought to independently cause monogenic PD, the non-idiopathic version of the 
disease, although these six gene variants altogether only explain 3-5% of PD occurrence (Klein 
& Westenberger 2012). Also, epidemiological studies using monozygotic and dizygotic twins 
suggest that in late-onset PD environmental factors are more important than in early-onset PD, 
where genetic factors seem to be more relevant (Wirdefeldt et al. 2011). Other epidemiological 
evidence has linked PD with various exogenous factors such as pesticides, metals, dietary habits, 
and occupational history, of which only pesticides and intake of dairy products show some 
consistency of results (see Wirdefeldt et al. 2011 for a comprehensive review).
Th e disorder strongly aff ects a region of the brain called substantia nigra, which is involved 
in motor control and coordination, by severely impairing and killing dopaminergic neurons. 
Dopaminergic transmission to the striatum is important in the regulation of voluntary and 
involuntary muscle movements. A classic pathologic feature of the PD-aff ected brain is the 
presence of Lewy bodies, which consist of inclusions of accumulated alpha-synuclein fi brils. 
Lewy bodies are believed to be aggresomes, inclusions of misfolded proteins derived from the 
inability of cells to degrade them. Alpha-synuclein is abundant in the presynaptic axon terminals. 
Its function is not well understood, but it is thought to be involved in maintaining the supply of 
synaptic vesicles at the axon terminal’s active zone for release (Diao et al. 2013).
Braak and colleagues (Braak et al. 2003a, Braak et al. 2004) have suggested the following 
sequence of events for the brain pathology of PD:
a) before the manifestation of PD-related motor symptoms, Lewy bodies appear in the dorsal 
motor nucleus of the vagus nerve and the pathology spreads from there to the medulla 
oblongata/pontine tegmentum (which are associated with breathing, heart rate, and blood 
pressure control; and with sensory and motor functions, control of the stages of sleep, 
respiratory rate, and arousal and vigilance, respectively). Th e olfactory bulb/anterior olfactory 
nucleus is also aff ected at this stage, followed somewhat later and independently by the lower 
raphe nuclei;
b)  as the disease progresses, it spreads to the substantia nigra and adjacent areas of the midbrain 
and forebrain, and possibly the fi rst classical symptoms (i.e. motor) appear;
c)  fi nally, the pathology spreads throughout the neocortex, which has functions related to 
sensory perception, motor control, and language, among others.
Th is sequence of events has become known as the Braak Hypothesis, and given its association 
with the vagus nerve, it led to the suggestion that PD could be aetiologically related to an 
environmental agent (a bacterium, a virus, or a toxin) entering the human body through the 
nose and then from there to the gut, subsequently gaining access to the central nervous system 
(CNS) aft er breaching the gut mucosal barrier, and from there spreading into the brain (Braak 
et al. 2003b). In fact, it is known that PD pathology (i.e. Lewy bodies) aff ects not only the CNS 
but also the peripheral nervous system (PNS) and particularly the enteric nervous system (ENS), 
including in putative pre-symptomatic cases (Wakabayashi et al. 1988, Braak et al. 2006, Dickson 
et al. 2008, Beach et al. 2010, Lebouvier et al. 2010, Shannon et al. 2012, Visanji et al. 2013). 
Th e environmental agent would therefore gain entry to the neural axons (nerve fi bers that 
conduct electric impulses) of the ENS through the enteric epithelium and be transported trans-
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5synaptically to the CNS via the vagus nerve into the medulla. Regarding entry into neurons, the 
uptake of substances from outside the neuronal space at the axon terminals is known to occur, 
with several neuroactive substances commonly gaining entry in this way (e.g. through receptor-
mediated endocytosis; Braak et al. 2003b). Th is could provide the possible route of entry into 
the nervous system for a putative pathogenic agent. Also, olfactory and taste dysfunction is 
common in early PD, as well as early Lewy pathology of the olfactory bulb and oral raphe nuclei, 
although this would not be the preferred route of pathology spread into the brain. Instead, the 
pathology would essentially be restricted to the olfactory and oral areas, given that the observed 
pathology doesn’t seem to spread substantially to the brain from these peripheral areas (Braak 
et al. 2003b). Th is led to the suggestion that the nasal route could be involved in tandem with a 
gastrointestinal origin, aft er swallowing nasal secretions containing the putative agent. Th e oral 
route would probably not be the main point of origin of the disease because the pathology seems 
to manifest at this location later than in the nasal structures, and also because direct neuronal 
connections exist only between the main olfactory areas and the substantia nigra (Hawkes et 
al. 2007, Lerner & Bagic 2008, Sengoku et al. 2008, Del Tredici & Braak 2016). It’s interesting 
to note in this context that there is experimental evidence for the entry of neurotropic viruses 
into the brain through the nasal route (Hawkes et al. 2007). On the other hand, Beach et al. 
(2010) showed support for greater involvement of the oral areas, with their study showing alpha-
synuclein pathology of the submandibular glands in PD, which are salivary glands and could be 
related to the decreased saliva production in PD. In fact, within the gastrointestinal tract, the 
submandibular glands and the lower oesophagus were the most aff ected areas, followed by the 
stomach, small bowel, large bowel, and rectum, in order of decreasing pathology severity. No 
pathology was found in the upper oesophagus.
Evidence has been presented that alpha-synuclein could behave as a prion, essentially 
being the driver of the pathology (Li et al. 2008, Visanji et al. 2013, Kordower 2014, Chauhan 
& Jeans 2015, Chu & Kordower 2015). Misfolded proteins, including alpha-synuclein in PD, 
could be associated with various neurodegenerative disorders, including via cell to cell spread 
from the ENS to the CNS (Lerner & Bagic 2008, Aguzzi & Rajendran 2009, Brundin et al. 
2010, Natale et al. 2011a, Natale et al. 2011b, Polymenidou & Cleveland 2011, Prusiner 2012, 
Olanow & Brundin 2013). A number of lab experiments, both in vitro and in vivo, have also been 
conducted regarding this hypothesis (see previous references in this paragraph for reviews), with 
one of the most interesting involving rats injected with misfolded alpha-synuclein that showed 
that amyloid pathology can spread using axonal transport in a prion-like form from the gut to 
the brain (Holmqvist et al. 2014). Another study showed that induced overexpression of human 
alpha-synuclein in the brain of rats resulted in accumulation in the vagal terminals of stomach 
walls (Ulusoy et al. 2017). In the fi rst study the route of spread was confi rmed to be the vagus 
nerve, and this was very probably the case also in the second study. Th ese results refl ect the 
issue that detection of pathology at a particular location does not by itself translate into place 
of initiation of disease spread. In fact, Beach et al. (2010) have suggested, based on their study 
results, the reversed order of events, with alpha-synuclein pathology possibly spreading from 
both the olfactory regions and the brain to the gut. Del Tredici and Braak (2012) also produced 
evidence in support of this hypothesis, showing that the spinal cord may get aff ected only aft er 
the brain.
Regardless of place of pathology initiation and spread direction, it is also possible that 
the misfolded alpha-synuclein is somehow related to a microbial agent. For example, β-N-
methylamino-L-alanine (BMAA) has been found to be elevated in parkinsonism-dementia 
complex of Guam  (Banack et al. 2010, Bhattacharjee & Lukiw 2013). BMAA is an oxidative 
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6stress-inducing neurotoxin in the form of an amino acid that is speculated to be produced by 
Melainabacteria, a group of fl agellated, obligate-fermenting, molecular hydrogen producing, B 
and K vitamin synthesizing, non-photosynthetic cyanobacteria found in the human gut, which 
were originally classifi ed as their own phylum but are now included in the phylum Cyanobacteria 
(Di Rienzi et al. 2013, Soo et al. 2014, Soo et al. 2017). More interestingly, BMAA has been linked 
to intra-neuronal protein misfolding and neurodegeneration. Also, a recent study using mice 
models for Alzheimer’s disease showed that the diseased mice’s gut microbiota not only diff ered 
from healthy control mice, but that diseased gnotobiotic mice had substantially lower amounts 
of Aβ-amyloid plaque in their brains than the diseased non-gnotobiotic mice. By transferring 
gut microbiota from non-gnotobiotic diseased and non-diseased mice into “healthy” gnotobiotic 
mice, the researchers showed that the latter developed signifi cantly more amyloid plaques if the 
transfer was made from the diseased mice (Harach et al. 2017). It is also interesting to note in 
this context that the gut microbiota widely produces functional amyloid peptides for biofi lm 
formation, cell aggregation, host-cell adhesion, toxins, and protection against host defences 
(Larsen et al. 2007, Blanco et al. 2012, Garcia et al. 2013, Hufnagel et al. 2013, Mulligan & 
Chakrabartty 2013, Schwartz & Boles 2013, Hill & Lukiw 2015). For example, Escherichia coli, 
as well as others in the Enterobacteriaceae family, naturally produces a functional amyloid, curli, 
from at least six proteins encoded by two operons (Barnhart & Chapman 2006). Th e major 
peptide structural subunit, CsgA, contains amyloidogenic repeat motifs shared by human prions 
and by alpha-synuclein (Chen et al. 2016b). Cross–seeding, in which one amyloidogenic protein 
initiates aggregation of a diff erent amyloid protein, has been demonstrated experimentally 
(Lundmark et al. 2005). Chen et al. (2016b) showed evidence that cross-seeding between 
curli and alpha-synuclein occurs by exposing aged Fischer 344 rats and transgenic nematodes 
(C. elegans expressing human alpha-synuclein) to wild-type curli-producing E. coli, with the 
control rats and nematodes being exposed to engineered E. coli lacking the curli-production 
operons. Th e aged rats, orally exposed to the bacteria, showed enhanced alpha-synuclein 
aggregation in the brain and deposition in the gut, while the nematodes, who naturally feed on 
E. coli, showed increased alpha-synuclein aggregation starting in the head and then spreading to 
the tail.
Abnormal microbial community composition and structure could also conceivably lead 
to neurological disease, as opposed to a particular microbial agent. For example, a signifi cant 
number of neuroendocrine hormones are produced by bacterial communities in the animal gut, 
many of them sharing the same protein structure and biosynthetic pathways found in mammal 
lineages, e.g. members of the catecholamine family, like tyrosine and epinephrine (adrenaline), 
complete pathways of which can be found in Escherichia coli and other bacteria, acetylcholine, 
histamine, serotonin, agmatine, GABA, and various others. More importantly, some of these 
have been found in amounts theoretically capable of eliciting physiological responses in the 
animal host (Lyte & Cryan 2014). Th us, bacteria as well as other microorganisms (e.g. yeasts) 
are capable of producing, as well as responding to, the same neurohormones utilized by the host, 
since many possess receptors for these neuroactive substances, in some cases with high-affi  nity 
such as in Pseudomonas (Guthrie et al. 2000). It is not, however, clear what the function of these 
neuroactive chemicals are in microorganisms, with a few exceptions like e.g. GABA, which seems 
to be involved in resistance to acidic pH in some Lactobacillus species and in the germination of 
Bacillus spores (Foerster & Foerster 1973, Su et al. 2011). It is quite possible that these substances 
are used as chemical signals in quorum-sensing. Th is opens the possibility that microbe-host 
bidirectional signalling occurs. For a comprehensive review of these matters see Lyte & Cryan 
(2014) and references therein. Th us, our two pilot studies on PD (I & II) aimed at obtaining clues 
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infectious agents in accordance with the Braak Hypothesis, as well as insight into possible overall 
community dysfunction.
1.3.  The Ra? onale for Microbiome Studies in Primary Sclerosing 
Cholangi? s
Primary Sclerosing Cholangitis (PSC), like Parkinson’s, is an idiopathic disease. In PSC, chronic 
infl ammation of the liver leads to strictures of the bile ducts and eventually to cholestasis 
and secondary biliary cirrhosis (Hirschfi eld et al. 2013). Th e infl ammation is associated with 
a substantially increased risk of development of biliary dysplasia and cholangiocarcinoma 
(Bergquist et al. 2002). PSC results from obstruction of the bile ducts and biliary epithelial tissue 
damage, mediated by infl ammation, leading to decreased bile fl ow and accumulation of toxic 
bile products. Together with Primary Biliary Cirrhosis (PBC), they represent the major clinical 
pathologies in chronic cholestatic liver disease (Mattner 2016).
Liver produces bile, which fl ows through the hepatic ducts into the gallbladder, where it is 
stored and concentrated mostly by removal of water, and from which it is then released into the 
duodenum through the common bile duct. Bile consists mostly of water and bile acids. Th ese 
acids serve several important functions, among which is the inhibition of bacterial growth and 
adhesion for protection against bacteria ascending from the small intestine through the biliary 
tract. For this purpose, bile is combined with secreted immunoglobulin A (IgA; Wu et al. 2004, 
Mattner 2016). Th e formation of mucins by the biliary epithelial cells to form a mucus layer, 
the presence of bacterial cell wall breakdown products including lipopolysaccharides (LPS) 
and lipoteichoic acid in human bile, as well as the local expression of immune receptors and 
production of antimicrobial peptides in the biliary tract, all indicate that the bile tract is prepared 
for the presence of bacteria and the risk of infection (Sasatomi et al. 1998, Tsuneyama et al. 2001, 
Verdier et al. 2015).
Obstruction of the bile fl ow in PSC not only damages the integrity of the epithelial layers 
of the bile ducts but may also leads to alterations in putative microbial bile communities (e.g. in 
the gallbladder) and to an increase in the susceptibility to infection (Miyake & Yamamoto 2013, 
Verdier et al. 2015). For example, it is known that a number of microorganisms are resistant to 
bile acids, such as Escherichia coli and Helicobacter spp. (Brook 1989, Fox et al. 1995, Carpenter 
1998, Ganzle et al. 1999, Hirai 1999). Nevertheless, a healthy biliary tract has until very recently 
been considered to be a sterile one (Verdier et al. 2015). In general, putative biliary microbial 
communities appear to be similar to those of the upper digestive tract, and have been suggested 
to originate from the small intestine (Shen et al. 2015, Ye et al. 2016), although there is no 
agreement on what a “healthy” microbial community, if any exists, should be like (Verdier et al. 
2015).
It has been suggested that microorganisms, microbial metabolites or derivatives could be 
associated with the etiopathogenesis of PSC (Tabibian et al. 2013, Eksteen 2014, Tabibian et al. 
2014, Mattner 2016). Th ere have also been a number of studies that provide indirect evidence 
for the involvement of microorganisms in the aetiology of PSC and/or in the disease’s progress. 
For example, decreased bile acid secretion has been linked to SIBO in liver cirrhosis (Bauer et 
al. 2001). Th ere is also a close association between PSC and infl ammatory bowel disease (IBD), 
which is thought to be linked to dysbiosis of the gut (Loft us et al. 1997, Packey & Sartor 2009, 
Reiff  & Kelly 2010, Eaton et al. 2013, Karlsen & Boberg 2013). Bacteria have also been cultured 
frequently from the bile of patients with acute cholangitis or cholecystitis, and most are found 
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8also in the intestinal tract, e.g. Escherichia coli, Klebsiella, Enterobacter, Pseudomonas, and 
Citrobacter spp. (Csendes et al. 1996). More importantly, their detection has been associated 
with disease progression to severe cholangitis and increased mortality rates. An experiment that 
consisted in inducing SIBO in the small intestine of rats triggered hepatobiliary infl ammation 
in a way that resembled the histological and cholangiographic features of PSC (Lichtman et al. 
1991). Furthermore, administration of an enzyme for peptidoglycan degradation, mutanolysin, 
to those rats improved the observed hepatobiliary pathology and also reduced infl ammation 
(Lichtman et al. 1992).
Evidence of a more direct nature exists for a link between bacteria and PSC in humans. 
Starting with colonic bacteria, a study based on ileocecal biopsies and using phylogenetic 
microarrays found that, compared to ulcerative colitis (UC) and controls, colonic mucosa-
associated microbiota in PSC showed lower diversity and a reduced abundance of uncultured 
Clostridiales II (Rossen et al. 2015). Some studies of gut communities have also been performed 
with DNA sequencing-based methods, with one study based on biopsies of the terminal ileum 
and the large intestine fi nding that the Barnesiellaceae family, the genus Blautia, as well as a 
number of OTUs (Operational Taxonomic Units) mostly from the order Clostridiales were 
enriched in PSC (Torres et al. 2016). Finally, two studies using stool samples found increased 
abundances for the genera Enterococcus, Fusobacterium, and Lactobacillus (Sabino et al. 2016), 
and Veillonella (Kummen et al. 2016) when comparing healthy controls to PSC patients, with 
both studies also fi nding lower bacterial diversity in PSC.
Finally, bile-based studies in PSC have also been performed, with an early study showing 
that diverse bacteria, particularly alpha-haemolytic streptococci, could be cultured from bile 
samples of patients with PSC, but not from those with primary biliary cirrhosis, thus also 
suggesting that contamination was not an issue in their studies since the methods of extraction 
used were the same (Olsson et al. 1998). Th ey also suggested that previous endoscopic retrograde 
cholangiography (ERC) procedures were the likely source of the identifi ed bacteria, ultimately 
originating from the small intestine. A more recent study used 16S rRNA gene amplicon 
sequencing to characterize the biliary bacterial communities of 39 PSC patients (Folseraas et 
al. 2012), but this study focused on possible links between microbial communities and human 
genetic features, and did not include any non-PSC controls. Th us, our study (III) represents a 
timely addition to this body of work on PSC, investigating the microbial communities in bile 
retrieved during ERC examinations, as well as the possible role for microbiota both in the 
aetiology of PSC and in the disease’s progression.
1.4.  The Role of Exploratory Studies in Human Microbiome Research
A criticism that is occasionally levelled against exploratory studies such as the ones presented in 
this thesis (I, II, III) is that they represent “hypothesis-free” research. Th is is a misunderstanding 
of the role these studies play in biomedicine in particular, and of exploratory research in general. 
Present scientifi c knowledge on microbiota-host interactions, on specifi c microorganisms, as well 
as on the potential role of the latter in a specifi c disease, is not developed to such an extent that 
would make it possible to formulate a specifi c scientifi c hypothesis amenable to translation into 
a clear-cut statistical hypothesis that could in turn be formally investigated, as is the case in e.g. 
experimental studies (Figure 1). Let us say that we want to test a certain scientifi c hypothesis, well-
grounded on previous knowledge, that a particular microorganism should be overrepresented 
in a given population. In this case, we could design an observational (and confi rmatory) study 
that would allow us to target specifi cally that organism and test our hypothesis. We wouldn’t 
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paradigm of Neyman and Pearson, since we could simply obtain point estimates for population 
abundance means and associated confi dence intervals as measures of uncertainty (Cumming 
2012, Rothman 2012).
Unfortunately, this is not possible in the kind of studies presented in this thesis. Our 
scientifi c hypotheses are of a more general character and there are no specifi c target organisms, 
as shown in the previous sections of the Introduction. Instead, what we want to know is if there is 
evidence for the involvement of any group of organisms in a disease, with diff erential abundance 
being a proxy for said potential involvement. To do this in practice, we need to use p-values 
under a NHST framework, or some other method that allows us to set a pre-specifi ed threshold 
of interest to red-fl ag results from a screening procedure. Th e reason is that, given the immense 
number of taxa seen in human microbiome studies (hundreds to thousands per dataset), we need 
to fi lter the most promising results, and NHST provides a convenient and acceptable method 
to perform said fi ltering, if used cautiously. p-values can be verbally defi ned in the following 
way: assuming that the null hypothesis of zero eff ect is true, what is the probability of observing 
an eff ect at least as extreme as the one observed in this study, just by chance (Motulsky 2010)? 
In NHST this idea is extended further: above a certain alpha cut-off  (usually set at 0.05) the 
results are considered as not providing enough evidence to reject the null hypothesis. Below the 
threshold, they are considered statistically signifi cant. Essentially, NHST provides an automated, 
dichotomous answer, i.e. either there’s a “diff erence” or there isn’t, based on an arbitrary threshold 
under the form of the alpha (the signifi cance level of the test). In practice, we need to acknowledge 
that using some kind of fi lter is desirable in the context of these studies, such that taxa whose 
diff erential abundances are statistically signifi cant are aft er detection paid particular research 
attention.
A related criticism sometimes levelled against p-values in general and NHST in particular, 
e.g. Kruschke (2015), Cumming (2012), Gelman et al. (2014), is essentially that the null 
hypothesis is already known a priori to be false in most cases. Th ere will (almost) always be some 
level of real variation, no matter how small the eff ect, associated with any comparison between 
populations, such that if we had unlimited access to samples we could always fi nd a statistically 
signifi cant diff erence. Th erefore, the question is usually one of degree of diff erence, not if there 
is a diff erence. Although this is essentially correct, we nevertheless still need in practice to 
Figure 1. General overview of the relationship between observational and experimental studies. 
More specifi c types of studies can fall into multiple categories. For example, case-control studies like the 
ones presented in this thesis can be used in either exploratory or confi rmatory studies.
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Figure 2. A simplifi ed view of possible eff ects and their relationship to sample size. Arrows denote 
increasing sample size. Notice that the fi gure is simplistic and for illustrative purposes only, e.g. chance 
eff ects can potentially occur even when the sample size is estimated as being “large” and adequate for 
detecting a hypothetical real eff ect.
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use some form of fi lter to screen massive amounts of data, for the reasons argued above. For 
that purpose, the defi nition of a p-value has sometimes been colloquially reformulated into 
something more operational: assuming that the null hypothesis is, for all practical purposes 
statistically indistinguishable from zero, what is the probability of observing an eff ect at least as 
extreme as the one observed, just by chance? Aft er obtaining the statistically signifi cant results, 
one can then assess their eff ect sizes, data patterns, uncertainty estimates, etc, and ponder their 
potential biological relevance. If the eff ect is deemed biologically meaningless in a particular 
research context (e.g. very small but statistically signifi cant eff ect size), then it can be ignored. 
Th us, exploratory studies are best seen as hypothesis-generators, since any clues derived from their 
results can then be used to conceive specifi c hypothesis amenable to investigation with targeted 
studies designed with that aim in mind. Th is means that our concern is not to demonstrate that 
there is defi nitely and beyond any reasonable doubt a connection between the microbiota and 
a given disease, but instead to evaluate if there is evidence for such a connection and if that 
evidence is substantial enough to warrant further investigation and/or to substantiate previously 
existing studies, especially if they used diff erent methods from ours.
Finally, there is the question of sample size and statistical power (Figure 2). In experimental 
studies or in observational but confi rmatory studies the researchers may have a clear idea of the 
eff ect sizes they deem interesting, as well as information on the expected standard deviations of 
the distributions of their variables of interest. However, this is usually not the case in exploratory 
studies such as the ones presented here. Th ere are several reasons why this is the case. First, the 
eff ect that the explanatory variables may have on the dependent variable is usually not known or 
it is known only in broad qualitative terms. Second, the variation associated with the explanatory 
variable (in this case taxon abundance) is also not suffi  ciently constrained to allow meaningful 
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power calculation for a particular eff ect size. Th ird, we usually do not have enough biological 
knowledge to a priori determine what a meaningful eff ect size would be. And fi nally, we have to 
deal with hundreds to thousands of diff erent taxa at the same time, and each of these will be a 
dependent variable in an associated statistical model. Th erefore, in practice, power calculations 
for determination of sample size are usually not practical in the context of these studies. Th e 
practical alternative relies on a combination of the researchers’ experience with data from human 
microbiome studies, background biological knowledge relevant to the problem at hand, and data 
from previously published studies that can potentially serve as a guideline (Debelius et al. 2016).
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2.  AIMS OF THE STUDIES
For the two Parkinson’s disease studies (I & II), the objectives were:
1)  to investigate the presence or absence of support for the hypothesis that PD could be 
aetiologically related to a putative pathogen invading the host from the gut, nasal, and/or oral 
areas. We specifi cally investigated the possibility of existence of a bacterial agent, although 
others are also conceivable (e.g. viral). A direct test of this hypothesis was not the aim here, 
since the studies were not designed to directly assess causality; instead, the studies were built 
as a fi rst step in the assessment of the hypothesis.
2)  We also aimed at evaluating the more general possibility that overall bacterial community 
composition and structure could be associated with PD, causally or not.
3)  Finally, we also aimed at assessing the potential of microbiota to be used as biomarkers in PD.
To achieve these objectives, we used high-throughput 16S rRNA gene sequencing methods that 
allow the determination of the presence and relative amounts of most bacterial taxa in the most 
unbiased way possible.
As for Study III on bile microbiota and Primary Sclerosing Cholangitis, the aims were:
1)  to compare bacterial abundances in controls to early disease stage PSC patients (ERC severity 
score <6) at their fi rst ERC examination as a way to avoid any confounding eff ects derived 
from the ERC interventions, and to evaluate the evidence obtained (or lack of it) for the 
involvement of bacteria in the aetiology of the disease. Another statistical model was also used 
in which all early stage patients were included (to increase statistical power) while controlling 
for the potential eff ects of the number of ERC examinations directly through modelling.
2)  To compare bacterial abundances during disease progression between early disease stage PSC 
patients and advanced disease stage patients (ERC severity score ? 6), while controlling for 
the number of ERC examinations through statistical modelling.
3)  To compare bacterial abundances between the advanced disease stage and the dysplasia/
carcinoma stage, while controlling for the number of ERC examinations through statistical 
modelling.
4)  To assess bacterial diff erential abundances and their relationship to disease by using the 
ERC severity score directly, while controlling for the number of ERC examinations through 
statistical modelling.
5)  And fi nally, to examine the impact of the number of ERC interventions on the microbiota, 
since previous reports suggested that cannulation during ERC procedures could be associated 
with infection of the bile ducts. 
As in the case of studies I & II, we used high-throughput 16S rRNA gene sequencing methods 
that allow the determination of the presence and relative amounts of most bacterial taxa in the 
most unbiased way possible.
Aims of the Studies
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3.  MATERIALS AND METHODS
3.1.  DNA Library Prepara? on and Sequencing
3.1.1.  Parkinson’s Disease
Table 1 presents general clinical data for the study populations in Studies I and II. Only the main 
clinical variables are presented here. For more information consult the respective articles and 
supplementary material.
Table 1. Selected clinical data for Studies I & II.
Study Number of 
Subjects
Selected Clinical Data %
(C & PD)
Female 
Subjects %
Age
(years, mean ± SD)
I
72 (C) vs 72 (PD)
PD Motor 
Phenotype (n/72):
TD: 23/72
MX: 9/72
PIGD: 40/72
IBS (resolved): 2.8% & 1.4%
*Wexner Score (median, IQR):
2 [1-4] & 5 [3-9]
*Atrial Fibrillation: 18.1% & 4.2%
*TIA or Ischemic Stroke: 37.5% & 7.0%
*Levodopa: 54.2% (PD only)
*COMT Inhibitor: 15.3% (PD only)
*Dopamine Agonist: 77.8% (PD only)
*MAO Inhibitor: 70.8% (PD only)
*Anticholinergic: 8.3% (PD only)
*Warfarin: 15.3% & 1.4%
*Statin: 54.2% & 20.8%
50.0 (C)
&
48.6 (PD)
64.5 ± 6.9 (C)
&
65.3 ± 5.5 (PD)
II
Oral:
76 (C) vs 72 (PD)
Nasal:
67 (C) vs 69 (PD)
*Atrial Fibrillation:
O: 17.1% & 4.2%, N: 19.4% & 4.4%
*TIA or Ischemic Stroke:
O: 35.5% & 5.6%, N: 37.3% & 5.8%
*Levodopa (PD only):
O: 52.8%, N: 52.2%
*COMT Inhibitor (PD only):
O: 13.9%, N: 16.0%
*Dopamine Agonist (PD only):
O: 77.8%, N: 80.0%
*MAO Inhibitor (PD only):
O: 68.1%, N: 71.0%
*Anticholinergic (PD only):
O: 8.3%, N: 8.7%
*Warfarin:
O: 14.5% & 1.4%, N:16.4% & 1.5%
*Statin:
O: 54.0% & 20.9%, N: 54.0% & 19.0%
Oral:
50.0 (C)
&
51.4 (PD)
Nasal:
50.8 (C)
&
49.3 (PD)
Oral:
64.3 ± 7.0 (C)
&
65.4 ± 5.5 (PD)
Nasal:
64.4 ± 6.8 (C)
&
65.3 ± 5.6 (PD)
C: controls. PD: Parkinson’s patients. O: oral. N: nasal. TIA: Transient Ischemic Attack. IBS:
Irritable Bowel Syndrome. * denotes statistical signi? cance in C vs. PD. Only the more relevant 
clinical variables are depicted in this table. For full details consult the supplementary material of the 
respective articles. All but two PD patients were under one or more antiparkinsonian medications, 
and two PD patients were treated by Deep Brain Stimulation (DBS).
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3.1.1.1. Gut Study
Faecal samples were collected by the study subjects at home using specialised collection tubes 
pre-fi lled with Stool DNA Stabilizer (as part of the PSP? Spin Stool DNA Plus Kit package 
from STRATEC Molecular). Transfer to freezers at -80 ?C occurred within three days of stool 
collection. Bulk DNA was extracted from the stool samples (PSP? Spin Stool DNA Plus Kit from 
STRATEC Molecular, as per the manufacturer’s instructions), and PCR was performed in two 
separate rounds of amplifi cation. During the fi rst round, we used “universal” bacterial primers to 
amplify the V1-V3 regions of the 16S rRNA gene (Edwards et al. 1989, Lane 1991), with pA and 
pD’ primers containing 18-mer overhangs in their 5’ ends. Between 3.6 and 60 ng of template 
DNA were used in this fi rst PCR round for each of three technical replicate reactions per 
sample, with a master mix containing Phusion polymerase (Finnzymes / Th ermo Scientifi c), HF 
buff er, and 2.5% DMSO. Th e replicate products were then pooled and purifi ed with Agencourt? 
AMPure? XP magnetic beads (Beckman Coulter). A second PCR round was then performed in 
which primers containing complementary sequences to the 18-mer overhangs are added, along 
with the Roche 454 adapter sequences added to the 5’ ends and followed by an index in the 
pA primer. Th e cycling conditions for both PCR reactions are the following: initial denaturation 
at 98 ?C for 30 s, 15 cycles at 98 ?C for 10 s, 65 ?C for 30 s, and 72 ?C for 10s, followed by a 
fi nal extension at 72 ?C for 5 min. Th e fi nal products were then purifi ed again with Agencourt? 
AMPure? XP magnetic beads. An equimolar DNA solution was then prepared for sequencing 
using the 454-GS FLX Titanium chemistry (Roche Diagnostics).
3.1.1.2. Oral and Nasal Study
Th e wet lab protocol was similar to the one in section 3.1.1.1 but with the following changes: 
oral and nasal samples were collected using sterile cotton swabs at the clinic, and these were 
immediately placed into small containers in ice, followed by transfer to freezers at -80 ?C within 
20 min. Bulk DNA was extracted from both sample types with FastDNATM Spin Kit for Soil (MP 
Biomedicals). Th e same universal bacterial primer sequences were used as in 3.1.1.1. On the 
5’ ends of the primers we added the full forward and reverse Illumina sequencing primers, for 
pA and pD’ respectively, that served as overhangs for the second PCR round. Between 10.7 and 
158.2 ng of template DNA were used in the fi rst PCR round for each of three technical replicate 
reactions for the oral samples, and between 8.5 and 262.6 ng for the nasal samples. Th e master 
mix contained Phusion Hot-Start II polymerase (Finnzymes / Th ermo Scientifi c). Purifi cation of 
the pooled technical replicates from the fi rst PCR round was performed by enzymatic digestion 
with Exonuclease I and FastAP (Th ermosensitive Alkaline Phosphatase, Th ermo Scientifi c). 
Th e second PCR round used primers with Illumina adapters at the 5’ ends followed by partial 
Illumina sequencing primer sequences that will attach to the overhangs from the previous PCR 
round. Index sequences were built into the reverse primers. Th e cycling conditions for both PCR 
rounds were similar to the ones described in section 3.1.1.1 except for the number of cycles in 
each of the rounds: the fi rst used 15 cycles and the second one 18. Th e fi nal equimolar DNA pool 
was then prepared for sequencing on an Illumina MiSeq using the v2 600 cycle kit paired-end 
(325 bp + 285 bp).
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3.1.2.  Primary Sclerosing Cholangi? s
Table 2 presents general clinical data for the study populations in Study III. Only the main clinical 
variables are presented here. For more information consult Article III and its supplementary 
material.
Table 2. Selected clinical data for Study III.
Selected Clinical 
Variables
Controls
(n = 46)
Early Disease
Stage (n = 37)
Advanced Disease
Stage (n = 32)
Dysplasia /
Carcinoma (n = 11)
Female, n/total (%) 27/46 (59) 25/37 (68) 17/32 (50) 9/11 (82)
Age, years, mean (SD) 43 (15) 38 (14) 41 (13) 40 (15)
*IBD present, n/total (%) 9/46 (20) 25/37 (68) 20/32 (59) 8/11 (73)
*ERC Score, 0-16 (SD) 0 (0.0) 2.8 (1.1) 7.9 (1.8) 10.1 (2.3)
*No of ERCs, n (%): - - - -
1-2 a46/46 (100) 34/37 (92) 14/32 (41) 4/11 (36)
3-4 0/46 (0) 3/37 (8) 8/32 (24) 4/11 (36)
≥ 5 0/46 (0) 0/37 (0) 12/32 (35) 3/11 (27)
IBD: Infl ammatory Bowel Disease. ERC: Endoscopic Retrograde Cholangiography. * denotes 
statistical signifi cance between groups. a denotes only one ERC examination. Only the more relevant 
clinical variables are depicted in this table. For full details consult Table 1 in Article III.
Bile fl uid was obtained during ERC examinations using aspiration and divided into 1 ml plastic 
tubes that were immediately immersed in liquid nitrogen at -196 ?C and then placed in freezers 
at -20 ?C. Later they were moved to -80 ?C freezers until further processing. Bulk DNA was 
extracted using Invisorb? Spin Blood Mini Kit (Stratec Molecular). Th e PCR procedure was 
similar to the one in section 3.1.1.2, but with two technical replicates per sample. Between 2.8 
and 352 ng of template DNA were used during the fi rst PCR round per technical replicate. Th e 
fi nal equimolar pool was sequenced using the Illumina MiSeq v3 600 cycle kit paired-end (325 
bp + 285 bp).
3.2.  Data Analysis: Overview of the Methods
Aft er the biological samples are sequenced and the raw sequence data is obtained, the latter needs 
to be processed to produce biologically meaningful information that can be analysed by the end 
user. Th is essentially means converting the raw sequence data into lists of organisms present 
in their respective communities, including their relative abundances. Diff erent soft ware exists 
to perform these bioinformatic analyses. In microbial ecology and human microbiome studies 
the two most used soft ware packages are QIIME (Caporaso et al. 2010) and mothur (Schloss 
et al. 2009). Th ese are soft ware packages that allow an entire sequence processing pipeline to 
be performed without resorting to handling separate programs to perform specifi c functions. 
Instead, these generalist packages contain implementations of open source soft ware under 
the same user interface. mothur was used to handle all the sequence data in the three studies 
presented in this thesis (I, II, III). Th e main sequence processing steps in mothur consist of, in 
order:
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1)  Reduction of sequencing errors (removal of sequences with ambiguous base calls, removal 
of homopolymers above a defi ned maximum length, minimum average quality score per 
sequence, detecting and correcting sequencing errors in the form of base substitutions, etc). 
Reducing sequencing errors is important, since sequencing errors are diffi  cult to distinguish 
from true biological variation, thus artifi cially infl ating microbial diversity (Quince et al. 
2011, Schloss et al. 2011, Bragg et al. 2012, Kozich et al. 2013).
2)  Alignment of the dataset to an external database (we used SILVA, the default; Quast et 
al. 2013, Schloss 2009), and removal of sequences not overlapping with the target regions 
(V1-V3 regions of the 16S rRNA gene in our three studies).
3)  A fi nal step in denoising the dataset can be performed at this point, by pre-clustering the 
sequences, followed by a pre-specifi ed similarity threshold for sequence merging. We set the 
parameter to 4 instead of 2 nucleotides diff erence between a given sequence and a second, 
more abundant sequence, since our V1-V3 region is longer than the one described in the 
online protocol (circa 500bp).
3)  Identifi cation and removal of chimeric sequences produced by PCR amplifi cation, either 
during DNA library creation or potentially in the sequencing platform. We used the most 
abundant sequences as reference, which is the default approach, as opposed to using an 
external database e.g. SILVA (Meyerhans et al. 1990, Smyth et al. 2010, Edgar et al. 2011).
4)  Removal of undesirable sequences derived from chloroplasts, mitochondria, Archaea, and 
eukaryotes (18S rRNA) that get accidentally picked by the bacterial primers due to homology. 
Th e identifi cation and fi ltering of these sequences is done by aligning the reads to a reference 
database e.g. from the Ribosomal Database Project (RDP; Cole et al. 2009).
5)  An optional step at this stage is the removal of singleton sequences. It helps with processing 
power and also reduces the amount of false biological reads produced by sequencing errors 
e.g. low quality sequences at the end of the reads. If processing power isn’t an issue, removal 
of singletons can be performed prior to statistical analysis. In Study I we did not remove the 
singleton sequences at this stage, but instead prior to statistical analysis. Also, we used the 
phylotype approach in this study (see below), which produces less singletons. In the remaining 
two studies (II & III) we removed the singletons at this stage.
6)  Clustering and taxonomic classifi cation of the remaining sequences. For Study I we used 
the phylotype approach, and for the remaining two studies (II & III) we used the OTU-based 
approach. Th e phylotype approach relies on both binning and classifying the sequences 
according to sequence similarity to an external, curated database. We used the RDP database. 
Th e OTU-based approach relies on binning the sequences fi rst according to similarity to 
each other using the dataset as self-reference and then using an external database for the 
taxonomic classifi cation. We also used RDP in this case (Schloss & Westcott 2011, Rideout et 
al. 2014, Westcott & Schloss 2015).
In Study I, using the Roche 454 platform, we followed the instructions provided in the protocol 
by Schloss, publicly available online (Schloss et al. 2011; Schloss, access date July 2013). In 
studies II & III we used the Illumina MiSeq protocol, also freely available online (Kozich et al. 
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2013; Schloss, access dates October 2014 and June 2014, respectively). For a detailed treatment of 
sequence processing and related matters, see Meyerhans et al. 1990, Schloss 2009, Schloss 2010, 
Smyth et al. 2010, Edgar et al. 2011, Quince et al. 2011, Schloss et al. 2011, Schloss & Westcott 
2011, Bragg et al. 2012, Schloss 2013, Koskinen et al. 2015, Westcott & Schloss 2015.
For studies II & III we sequenced DNA extraction kit blanks and PCR blanks as 
contamination controls. Th is resulted in the removal of all sequences from the genera Halomonas, 
Ralstonia, and Shewanella, based on the presence and amount of reads on both control types and 
on published data on contaminants, as well as on personal experience with previous studies at 
our lab (Salter et al. 2014, Aho et al. 2015).
Statistical data analysis was performed with the R statistical programming language (R Core 
Team 2015) except otherwise noted. Th e package phyloseq (McMurdie & Holmes 2013) was used 
to manipulate the microbiome data in R’s environment. All p-values were double-tailed, with 
statistical signifi cance accepted at an alpha of 0.05. In Article I we used SPSS Statistics (IBM 
Corporation) for Generalised Linear Models (GLMs) and Receiver Operating Characteristic 
curves (ROC curves).
In the context of microbiome studies, alpha diversity is an estimation in the form of an 
index that takes into account the number of diff erent species or OTUs (richness) and how well 
represented they are relative to each other (evenness) in any given biological sample. We used 
mostly the Shannon and the inverse Simpson diversity indices in our work (Haegeman et al. 
2013). Study I was performed with rarefi ed data aft er removal of singletons. Studies II & III were 
performed using non-rarefi ed data aft er removal of singletons and decontamination. Although 
greater sequencing depth in any given sample has the potential to increase the number of 
OTUs observed (Weiss et al. 2017), these diff erences will balance out in practice for purposes 
of alpha diversity between-group comparisons (personal observation). Removal of singletons 
for calculation of diversity indices is usually frowned upon by some authors, but there are 
fundamental diff erences between the use of these indices in the traditional ecological literature 
and in DNA sequencing-based microbial ecology. Th ese indices were originally developed with 
macro-organisms in mind (Whittaker 1960), where taxa can be identifi ed with less ambiguity 
than phylogenetic marker genes. Also, given that many of these singleton sequences are the 
product of sequencing errors that can create artifi cial OTUs, it is desirable to remove them. 
Absolute diversity indices in microbial marker-gene surveys can only be eff ectively compared 
within-study, and thus a “true” index value valid for inter-study comparisons is essentially 
meaningless. Diff erences in alpha diversity were tested with Kruskal-Wallis rank sum tests and/
or Pairwise Wilcoxon rank sum tests, with False Discovery Rate (FDR) correction for multiple 
comparisons. Th ese tests are non-parametric and adequate for data whose distribution deviates 
from normality and, more importantly, for data that is heteroskedastic.
Beta diversity measures the composition of microbial communities (what species or 
OTUs are present and in what numbers) in the groups under contrast (sites, in the traditional 
ecological literature; Anderson et al. 2011). We used the Bray-Curtis dissimilarity index for 
these calculations, which produces a dissimilarity matrix based on pairwise sample diff erences, 
visualised the matrix data with Non-Metric Multidimensional Scaling (NMDS), and tested for 
diff erences between groups with the adonis function of the package vegan (Oksanen et al., access 
date 2015). For Article I, we used UNIFRAC in mothur instead of adonis (Lozupone & Knight 
2005, Lozupone et al. 2011). adonis is an implementation of PERMANOVA (Permutational 
MANOVA using Distance Matrixes), formerly known as Non-Parametric MANOVA (Anderson 
2001, McArdle & Anderson 2001). Th e data was rarefi ed before the estimations, since these will 
be sensitive to the presence or absence of particular taxa across compared groups. We informally 
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tested the latter and in some cases non-rarefi ed data leads to artefacts such as samples with more 
reads clustering together, very probably due to containing more (usually rare) taxa in common. 
Th us, we use rarefaction as a precaution, and in fact this has been shown to be a common 
problem with compositional data in beta diversity analysis (Weiss et al. 2017).
NMDS plots and adonis were also used to investigate potential batch eff ects resulting from 
DNA extraction batches, kit lot batches, PCR batches, and multiple sequencing runs. When 
the existence of potential eff ects was suggested by the analysis, we controlled for those eff ects 
during modelling (McNamee 2005, Leek et al. 2010). For a discussion of common problems with 
contamination and batch eff ects in 16S rRNA gene survey studies see e.g. Salter et al. (2014).
Collinearity and multicollinearity (when two or more explanatory variables in a model are 
substantially correlated with each other, respectively) were assessed with pair-plots of Pearson 
Correlation coeffi  cients and with Variance Infl ation Factors (VIF), for comparisons between 
continuous variables. For collinearity between continuous and categorical variables with more 
than two levels we used boxplots and Generalised VIFs. In case (multi)collinearity was detected, 
adequate variable selection was undertaken before running the GLMs (Ieno & Zuur 2015, Fox 
2016).
Logistic regression was used for prediction of PD status based on bacterial abundances 
and other explanatory variables in Article I. ROC curves were used to assess the discriminative 
performance of the various classifi er models in terms of sensitivity (true positive rate) and 
specifi city (true negative rate; Loong 2003).
Diff erential abundance analysis was performed with Metastats in Article I (White et al. 
2009), using mothur. Given that Metastats does not allow adjustment for potential confounders 
and consists, in general terms, in directly comparing pre-defi ned groups/variables of interest 
with the non-parametric t-test (Storey & Tibshirani 2003) and Fisher’s exact test for rare taxa, 
both with FDR, we had to further evaluate the statistically signifi cant hits preliminarily obtained 
from Metastats with GLMs. Taxa that were statistically signifi cant before correction for multiple 
comparisons with the FDR method were also further investigated with GLMs.
In studies II & III, diff erential abundance analysis was performed with Negative Binomial 
GLMs using the DESeq2 package for R (Love et al. 2014). Instead of rarefying the raw count data, 
DESeq2 normalises the data for sequencing depth, without the losses common to rarefaction 
(Hanski et al. 2012, McMurdie & Holmes 2014), using the median-of-ratios of observed counts’ 
method (Anders & Huber 2010), from which it estimates size factors. Th ese size factors are 
included as off sets directly in the models, and therefore there is no data normalisation prior 
to running the models. DESeq2 uses Logarithmic Fold Change (LFC) estimation for eff ect 
sizes: the null hypothesis for diff erential abundance testing is that the LFC (not the mean 
abundance of counts) between two statistical samples is zero. Th ese are estimated during a 
fi rst round of model fi tting using Maximum-Likelihood Estimation (MLE) of the log fold 
changes, using only individual taxon data. Because data with high within-group variances can 
lead to heteroskedasticity, to statistically signifi cant LFC estimates due to chance eff ects, or to 
biologically meaningless large fold change estimates, DESeq2 shrinks these raw LFCs towards 
zero. Th e greater the within-group variance, the more shrinkage is applied to a taxon’s LFC. Th e 
soft ware does this by calculating a prior distribution, based on the distribution of all observed 
LFCs across the dataset and to which a normal distribution centred on zero is fi t. Th is prior 
distribution is then used as a Bayesian prior (Empirical Bayes Shrinkage) for estimating the fi nal, 
adjusted LFCs when refi tting a second round of GLMs per individual taxon (Love et al. 2014).
Multiple comparisons’ correction was done using the Benjamin-Hochberg method (an 
FDR procedure) to avoid Type-I errors. We also fi ltered the data before running the GLMs as 
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an added precaution against biologically meaningless large fold changes or chance eff ects driven 
by low count taxa or by groups with low sample numbers (Giesecke 2002, Freedman 2009). Th is 
fi ltering was performed by removing from the dataset, prior to running the models, all taxa that 
weren’t represented by at least 2 sequences per biological sample in at least 11 biological samples 
across the dataset. Th is is a conservative approach, since DESeq2 performs automatic fi ltering. 
Th is procedure may lead to the unintended purge of potential keystone species from the dataset, 
but in the present framework it is a necessary compromise due to the need to minimize Type I 
errors.
Oligotyping was used to investigate the Staphylococcus OTU detected in the nasal data of 
Article II. Th e analysis was performed following the pipeline provided by the authors’ in Eren 
et al. (2013). Oligotyping is used to help diff erentiate between taxa obtained from 16S rRNA 
gene amplicons, since these may be unresolved at the desired taxonomic level due to limitations 
inherent in the sequence classifi cation methods available (e.g sequence similarity thresholds for 
clustering sequences into OTUs and/or incomplete reference databases). Unlike reference-based 
or clustering-based methods that compare all available sequence positions at the same time, 
oligotyping uses only the variable sites, aft er being identifi ed by entropy analysis, that optimize 
taxonomic granularity by focusing on information-rich nucleotide variation. Th e method does 
not depend on similarity of conserved regions of entire sequences, considering these redundant 
for fi ner taxonomic discrimination. Th us, the method will produce diff erentiated operational 
units, oligotypes, that are based on the minimal number of nucleotide positions in the taxon/
operational unit of interest that will explain the maximum amount of biological diversity 
within that taxon/operational unit (e.g. an OTU sequence cluster or all sequences classifi ed as 
a particular genus). Th ese oligotypes can then be subjected to diff erential abundance analysis. 
Th eir sequences can also be matched to a database and cladograms can be built to elucidate 
phylogenetic relationships.
Th e statistically signifi cant taxa resulting from the diff erential abundance models were 
further investigated using boxplots and scatterplots to look for signs of presence of chance eff ects 
that could result in Type-I errors. Th is was done by plotting the variable of interest and the 
relative abundance (or the normalised count data) of the taxon in question and investigating the 
patterns and spread of the data, e.g. for the presence of putative outliers, infl uential points with 
high leverage, very low mean abundances (e.g. of 1) regardless of eff ect size, inconsistent patterns 
of increasing and decreasing abundance across multiple groups that are diffi  cult to explain as 
biologically meaningful, etc. Th ese features are usually found in combination. When statistical 
signifi cance was suspected of being just an apparent eff ect derived from statistical noise, we took 
a conservative approach and removed the corresponding taxa from further consideration. Tables 
with all the obtained statistically signifi cant results were nevertheless provided, either in the 
Articles’ main text or in their respective supplementary materials.
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4.  RESULTS
4.1.  Parkinson’s Disease
With data from a recent, unpublished gut dataset using Illumina MiSeq sequencing and the 
same stool samples and subjects from Study I, we generated an NMDS plot to contrast the 
compositional data from gut, oral, and nasal samples (Figure 3). As can be seen, there is a clear 
compositional demarcation based on sampling location.
Figure 3. NMDS plot of PD data by sampling location. Ordination based on Bray-Curtis 
dissimilarity with genus-level data. Each point represents one subject.
4.1.1.  Gut Study
Th e original dataset consisted of 2 549 217 raw reads. Th e fi nal dataset used for statistical analysis 
aft er processing consisted of 1 131 504 reads, with a mean of 7 645 reads per subject. Th e overall 
taxonomic composition of the dataset refl ects the results of other studies on gut microbiota 
(e.g. Qin et al. 2010, Hasegawa et al. 2015, Keshavarzian et al. 2015). We detected 18 phyla, 29 
classes, 60 orders, 125 families, and 360 genera of bacteria, with the most common phyla being 
represented by Firmicutes and Bacteroidetes, which are the typically dominant phyla in the gut 
(Figure 4).
No diff erences in alpha diversity were found between the PD and control groups, suggesting 
that OTU richness and evenness are similar among the two populations (mean inverse Simpson 
index for controls = 20.6 vs. PD subjects = 21.8, p = 0.38; mean Shannon index for controls = 
3.7 vs. PD subjects = 3.8, p = 0.51, with Kruskal-Wallis rank sum test). On the other hand, beta 
diversity analysis suggested the existence of compositional diff erences at family-level between the 
bacterial communities of the two groups (Yue & Clayton theta, Morisita-Horn, and Bray-Curtis 
indices computed with family-level data; unweighted UniFrac p ? 0.02 and weighted UniFrac p < 
0.001 for all three indices).
Metastats identifi ed six families that were potentially diff erentially abundant, namely 
Prevotellaceae, Lactobacillaceae, Verrucomicrobiaceae, Bradyrhizobiaceae, Clostridiales Incertae 
Sedis IV, and Ruminococcaceae (Table 3). All were estimated as increasing in abundance in the 
PD group except for Prevotellaceae. Th e latter was the fourth most abundant family in the dataset 
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and showed the largest abundance diff erential: a decrease of 77.6% in PD relative to the control 
group (Figure 4, Table 3), with subjects with high abundances of Prevotellaceae not being present 
in the PD group (Figure 1 in Article I). 
Figure 4. Relative abundances of the 10 most abundant bacterial families in the dataset. 
The 10 and 5 most common families accounted for 91.6% and 81.3% of all reads, respectively.
Table 3. Metastats results. Family diff erential abundances, PD vs. Controls.
Family Patients Controls p-value Q-value
Prevotellaceae 2.70 ± 0.66 12.06 ± 2.28 0.001 0.031
Lactobacillaceae 0.44 ± 0.23 0.02 ± 0.01 0.004 0.063
Verrucomicrobiaceae 0.06 ± 0.02 0.02 ± 0.00 0.014 0.146
Bradyrhizobiaceae 0.16 ± 0.06 0.03 ± 0.01 0.021 0.151
Clostridiales Incertae Sedis IV 2.49 ± 0.65 1.01 ± 0.22 0.025 0.151
Ruminococcaceae 33.63 ± 1.66 28.54 ± 1.58 0.029 0.151
PD and control groups with an uncorrected p-value less than 0.05 (mean % ± standard error). 
Q-value: correction for multiple comparisons (FDR).
Given that Metastats does not permit adjustment for potential confounders based on the clinical 
data, we used GLMs with the six families above as response variables (Tables 1 and 2 in Article I). 
Prevotellaceae were shown to vary in abundance only in response to disease status, with no other 
model variable showing any detectable eff ect. All other families, except for Ruminococcaceae, 
were associated with disease status as well as with other clinical factors. Ruminococcaceae were 
found to be strongly associated only with Prevotellaceae abundance levels and not with disease 
status or any other clinical variable.
A ROC curve analysis based only on Prevotellaceae abundances had a sensitivity of 
86.1% and a specifi city of 38.9% for identifi cation of PD patients (Figure 2 in Article I). Using 
logistic regression with disease status as response variable and Prevotellaceae, Lactobacillaceae, 
Bradyrhizobiaceae, and Clostridiales Incertae Sedis IV abundances, as well as the Wexner total 
score (a clinical measure of constipation) as explanatory variables, enabled identifi cation of PD 
cases with a sensitivity of 66.7% and a specifi city of 90.3%.
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We made a PD subjects-only GLM analysis based on the UPDRS-III total score (Unifi ed 
Parkinson’s Disease Rating Scale; Part III refers to the clinician-scored motor evaluation), 
including subjects under normal medication and DBS (Deep Brain Stimulation). Th e response 
variables were the fi ve families previously found to be statistically signifi cantly associated with 
disease status. Although Prevotellaceae were statistically signifi cantly, and positively, correlated 
with increasing UPDRS-III severity, the statistical signifi cance was lost when subjects with motor 
fl uctuations and under DBS were removed from the analysis.
Metastats identifi ed Enterobacteriaceae as diff erentially abundant between the TD (Tremor 
Dominant) and PIGD (Postural Instability and Gait Diffi  culty) groups within the PD subjects, 
showing an increase in abundance in the PIGD group (Table 4, eFigure 2 in Supplement for 
Article I). Th is family was further investigated with two GLMs to evaluate possible correlations 
with the Tremor subscore, PIGD subscore, Akinetic-rigid subscore, and the NMSS total score 
(Non-Motor Symptoms Scale; Table 3 in Article I). Enterobacteriaceae abundance was found 
to be positively correlated with the PIGD and Akinetic-rigid subscores, and was very close to 
statistical signifi cance for a negative correlation with the Tremor subscore. Removal of subjects 
with motor fl uctuations or under DBS from the analysis results in only the PIGD correlation 
remaining signifi cant.
Table 4. Metastats results. Family diff erential abundances, TD vs. PIGD.
Family TD PIGD p-value Q-value
Enterobacteriaceae 0.28 ± 0.13 2.31 ± 0.81 0.004 0.018
Erysipelotrichaceae 1.17 ± 0.30 2.19 ± 0.32 0.024 0.103
TD and PIGD groups with an uncorrected p-values less than 0.05 (mean % ± standard error). 
Q-value: correction for multiple comparisons (FDR).
4.1.2.  Oral and Nasal Study
Alpha diversity was higher in the oral than the nasal dataset. Beta diversity analysis showed that 
the oral and nasal community compositions were very distinct (Figure 3). Also, the oral and nasal 
samples from any given individual (irrespective of PD status) weren’t more similar to each other 
than those of unrelated subjects (Wilcoxon rank sum test, p = 0.88 for Bray-Curtis dissimilarity 
between oral and nasal samples vs. unrelated pairs of samples; Figure S2 in the supplementary 
data for Article II), with the samples being more similar according to sampling location than to 
particular individuals (Figure 1 in Article II).
4.1.2.1.  Oral
Th e original oral dataset consisted of 21 645 150 raw reads. Th e fi nal dataset used for statistical 
analysis aft er processing consisted of 1 987 257 reads, with a mean of 13 427 reads per subject. 
We detected 15 phyla, 23 orders, 41 classes, 76 families, 129 genera, and 7996 OTUs. Th e 
taxonomic composition of the oral communities inferred from the data was consistent with 
previous fi ndings (e.g. Bik et al. 2010, Palmer 2014), with Streptococcus seemingly dominating 
oral communities (Figure 2A in Article II).
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No diff erence was detected in alpha diversity between PD subjects and controls (mean 
Shannon index for controls = 2.69 vs. PD subjects = 2.75, mean inverse Simpson for controls 
= 7.70 vs. PD subjects =  9.16; Kruskal-Wallis rank sum test, p ? 0.86 for both indices). Beta 
diversity analysis suggested the presence of diff erences in community composition between 
controls and PD (adonis, p = 0.01), and between genders regardless of PD status (adonis, p = 
0.05).
Th e most common genera in the oral dataset were Streptococcus, Haemophilus, Neisseria, 
Veillonella, and Prevotella (Figure 2A in Article II). PD status was the GLM variable associated 
with the greater number of detected taxon diff erential abundances, namely 11 families, 10 genera, 
and 25 OTUs (Table 5). Many of these taxa contain members that are known to be opportunistic 
oral pathogens. An increase in potential oral pathogen abundances was also detected in males 
relative to females, regardless of PD status. Minor results for other variables can be seen in Table 
2 of Article II, as well as in the supplementary tables for Article II.
Table 5. Diff erentially abundant (DESeq2: p < 0.05) taxa for oral data, Controls -> PD.
Taxon Mean Abundance
Log 2 Fold 
Change
SE of Log 2 
Fold Change p-value
Adjusted 
p-value
OTU
Otu000008 (Haemophilus) 419.00 -1.7031 0.3677 3.63E-06 1.94E-04
Otu000011 (Neisseria) 453.14 -2.6123 0.5175 4.46E-07 1.67E-04
Otu000009 (Gemella) 324.27 -1.0299 0.2745 1.76E-04 5.50E-03
Otu000017 (Rothia) 187.36 -1.282 0.4064 1.61E-03 2.51E-02
Otu000026 (Veillonella) 77.23 1.5349 0.3785 5.01E-05 2.09E-03
Otu000028 (Prevotella) 73.46 1.1903 0.3528 7.42E-04 1.48E-02
Otu000073 (Leptotrichia) 38.50 -1.801 0.5291 6.64E-04 1.47E-02
Otu000074 (Prevotella) 24.77 1.6926 0.5261 1.29E-03 2.11E-02
Otu000123 (unclassifi ed Flavobacteriaceae) 24.14 -1.5284 0.3142 1.15E-06 1.94E-04
Otu000127 (Corynebacterium) 21.66 -1.65 0.4696 4.42E-04 1.11E-02
Otu000118 (Kingella) 19.83 -1.5231 0.452 7.52E-04 1.48E-02
Otu000107 (Prevotella) 18.72 1.6819 0.3605 3.07E-06 1.94E-04
Otu000212 (Kingella) 9.50 -3.4138 0.7324 3.15E-06 1.94E-04
Otu000210 (Neisseria) 8.95 -2.8492 0.6129 3.34E-06 1.94E-04
Otu000231 (Corynebacterium) 8.11 -2.2211 0.5861 1.51E-04 5.15E-03
Otu000265 (Neisseria) 8.08 -2.3153 0.5992 1.12E-04 4.19E-03
Otu000352 (Neisseria) 4.77 -2.2078 0.6187 3.59E-04 9.62E-03
Otu000361 (Neisseria) 4.63 -2.0676 0.6323 1.08E-03 1.97E-02
Otu000355 (Neisseria) 4.52 -2.4536 0.595 3.73E-05 1.75E-03
Otu000367 (Actinomyces) 3.96 -2.0336 0.624 1.12E-03 1.97E-02
Otu000509 (Capnocytophaga) 2.05 -3.5443 0.9682 2.51E-04 7.25E-03
Otu000392 (Solobacterium) 1.86 1.3991 0.4079 6.04E-04 1.42E-02
Otu000448 (Kingella) 1.58 -4.9599 1.0673 3.37E-06 1.94E-04
Otu000418 (Prevotella) 1.55 2.3684 0.7288 1.15E-03 1.97E-02
Otu000806 (Veillonella) 0.28 2.0303 0.6551 1.94E-03 2.91E-02
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Taxon Mean Abundance
Log 2 Fold 
Change
SE of Log 2 
Fold Change p-value
Adjusted 
p-value
Genus
Haemophilus 1356.82 -1.021 0.3477 3.32E-03 2.07E-02
Gemella 673.01 -0.8461 0.3261 9.46E-03 4.73E-02
Neisseria 666.52 -1.4365 0.3233 8.87E-06 2.22E-04
Veillonella 410.55 0.7864 0.2301 6.31E-04 5.26E-03
Prevotella 283.03 0.9594 0.2408 6.76E-05 8.45E-04
Rothia 126.94 -1.1407 0.3106 2.40E-04 2.40E-03
Granulicatella 88.27 -0.715 0.2606 6.09E-03 3.38E-02
Kingella 28.79 -1.3791 0.3022 5.04E-06 2.22E-04
Moryella 2.34 0.9946 0.3175 1.74E-03 1.24E-02
Solobacterium 1.59 1.3087 0.3146 3.18E-05 5.30E-04
Family
Pasteurellaceae 2718.29 -0.8065 0.3292 1.43E-02 4.97E-02
Neisseriaceae 710.01 -1.3765 0.2851 1.38E-06 4.83E-05
Veillonellaceae 458.86 0.7763 0.2146 2.97E-04 2.60E-03
Prevotellaceae 349.18 1.0504 0.2351 7.86E-06 1.38E-04
Leptotrichiaceae 287.61 -0.5664 0.2099 6.96E-03 3.48E-02
Micrococcaceae 127.91 -1.1177 0.2942 1.45E-04 1.70E-03
Carnobacteriaceae 88.80 -0.789 0.2471 1.41E-03 8.20E-03
Corynebacteriaceae 77.91 -0.7095 0.2695 8.47E-03 3.71E-02
Lactobacillaceae 10.00 1.1188 0.4628 1.56E-02 4.97E-02
Coriobacteriaceae 5.84 0.7895 0.3128 1.16E-02 4.51E-02
Erysipelotrichaceae 1.84 0.9778 0.283 5.50E-04 3.85E-03
Model variables: taxon ~ extraction date + gender + age at sampling + history of ENT surgery + 
alcohol units per week + SDQ total + SCS-PD total + control vs PD.
4.1.2.2.  Nasal
Th e original nasal dataset consisted of 8 638 162 raw reads, and the fi nal dataset for statistical 
analysis consisted of 2 610 933 reads, with a mean of 19 198 reads per subject. We detected 28 
phyla, 49 classes, 96 orders, 177 families, 553 genera, and 2212 OTUs. Th e taxonomic composition 
of the nasal communities inferred from the data was consistent with that reported in previous 
fi ndings (Bassis et al. 2014, Biswas et al. 2015), with the dominant genus being Corynebacterium 
(Figure 2C in Article II).
No diff erences were detected in alpha diversity between controls and PD subjects (mean 
Shannon index for controls = 1.75 vs. PD subjects = 1.80, mean inverse Simpson for controls = 
4.86 vs. PD subjects =  4.69; Kruskal-Wallis rank sum test, p ? 0.65 for both indices). Notice that 
the mean values for the indices are not directly comparable between the oral and nasal datasets, 
since the raw sequence data was processed separately in mothur. Beta diversity analysis with 
adonis suggested that no compositional diff erences are present between controls and PD subjects.
Results
Table 5 cont.
25
Th e most common genera in the nasal dataset were Corynebacterium, Propionibacterium, 
Moraxella, Staphylococcus, and Burkholderia (Figure 2B in Article II). Only one taxon per 
each of the three taxonomic levels investigated were diff erentially abundant for PD status: a 
Staphylococcus OTU increased in PD, the genus Marmoricola, decreased in PD, and the family 
Flavobacteriaceae, also decreased in PD (Table 6, and Figure S5 in supplementary data for 
Article II). Minor results for other variables can be seen in Table 2 of Article II, as well as in 
the supplementary tables for Article II. Th e Staphylococcus genus was further investigated using 
oligotyping, which produced three oligotypes, one resembling S. epidermis, another S. aureus, 
while the last one was an unresolved Staphylococcus (Figure S6 in Supplement for Article II). Th e 
fi rst two composed 95% of all Staphylococcus reads. All were similar in relative abundance across 
PD and controls, producing no statistically signifi cant results.
Table 6. Diff erentially abundant (DESeq2: p < 0.05) taxa for nasal data, Controls -> PD.
Taxon Mean 
Abundance
Log 2 Fold 
Change
SE of Log 2 
Fold Change
p-value Adjusted 
p-value
Otu00006 
(Staphylococcus)
1512.91 3.9094 0.7019 2.55E-08 4.64E-06
Genus 
Marmoricola
4.56 -5.4099 1.4188 1.37E-04 1.78E-02
Family 
Flavobacteriaceae
31.50 -2.795 0.7322 1.35E-04 1.08E-02
Model variables: taxon ~ DNA extraction batch + gender + age at sample collection + history of 
non-major ENT surgery + snif? n’ sticks score + control vs PD.
4.2.  Primary Sclerosing Cholangi? s Study
Th e study subjects were classifi ed as follows for the purpose of investigating the research 
questions: controls (ERC severity score of 0, fi rst ERC examination), patients at an early disease 
stage (ERC severity score < 6), patients at an advanced disease stage (ERC severity score ? 6), 
and patients with biliary dysplasia/cholangiocarcinoma (Table 2).
Th e original bile dataset consisted of 22 795 599 raw reads, and the fi nal dataset for statistical 
analysis consisted of 3 740 318 reads, with a mean of 29 686 reads per subject. We detected 
20 phyla, 34 classes, 61 orders, 124 families, 309 genera, and 2125 OTUs. Th e most common 
phyla were Bacteroidetes, Firmicutes, and Proteobacteria (Figure 1a in Article III), and the most 
common genera in the dataset were Prevotella, Streptococcus, Veillonella, Fusobacterium, and 
Haemophilus (Figure 1c in Article III). Overall, these putative bile microbial communities show 
some similarity to gut communities (Hiramatsu et al. 2000, Folseraas et al. 2012, Shen et al. 2015, 
Ye et al. 2016).
Alpha diversity analysis with the Kruskal-Wallis rank sum test and Shannon index suggests 
that diff erences exist among the four subject groups (p = 0.036). To discriminate among the 
groups, we ran Pairwise Wilcoxon rank sum tests. Th ese suggest that the diff erences are associated 
mainly with controls vs. the dysplasia/carcinoma group (p = 0.055), and the early disease stage 
and the dysplasia/carcinoma group (p = 0.055; Figure 2a in Article III). All other comparisons had 
p = ? 0.164. Th e overall pattern suggests a progressive decrease in alpha diversity, with controls 
and early disease stage patients being virtually identical. Th e latter observation is substantiated 
Results
26
by a Pairwise Wilcoxon rank sum test using controls against early disease stage patients that 
had undergone only one ERC examination, to avoid potential ERC eff ects (p = 0.64; Figure 
2b in Article III). Beta diversity analysis suggested the presence of diff erences in community 
composition among the four study groups when the latter are not discriminated based on the 
number of ERC examinations (adonis, p = 0.05). When the groups are stratifi ed by number of 
ERC examinations (one vs. multiple) no diff erences were detected (adonis, p = 0.34), suggesting 
an eff ect of ERC examinations on community composition. Finally, both the ERC severity score 
and the number of ERC examinations seem to have an impact on community composition (p = 
0.06 and p = 0.02, respectively).
Diff erential abundance analysis resulted in a long list of taxa with statistical signifi cance 
for each of the groups and variables compared (Table S1 in Supplement to Article III). 
Comparing controls to early disease patients at their fi rst ERC examination resulted in four 
OTUs: an unclassifi ed Enterobacteriaceae (Otu0008), an unclassifi ed Neisseriaceae (Otu00213), 
Neisseria (Otu00045), and Campylobacter (Otu00089), as well as three families, Pasteurelaceae, 
Staphylococcaceae, and Xanthomonadaceae (Table 7). With controls and the early disease 
group as a whole (adjusting for the number of ERC examinations) we obtained two OTUs, an 
unclassifi ed Clostridiales, Otu00188, and the same unclassifi ed Neisseriaceae as before, Otu00213, 
and one family, Staphylococcaceae. However, visual inspection, very low abundances, and LFC 
considerations suggest that most of these results are Type-I errors (see also Figures S1 and S2 in 
Supplement to Article III).
Th e remaining models and comparisons identifi ed 24 taxa for early disease vs advanced 
disease stages, and 36 taxa for advanced disease vs dysplasia/carcinoma stages (Table S1 in Annex 
X to Article III).
Most of these statistically signifi cant taxa also showed a combination of features that renders 
them unconvincing as real biological eff ects. Th erefore, we decided to concentrate our attention 
only on those results that looked robust aft er assessment, although it is plausible that later studies 
may validate some of those results. Th e only clear, robust results refer to the streptococcal group 
and to a Prevotella OTU (Table 7, Figure 3a in Article III). From the early disease to the advanced 
disease group we saw an increase in the abundance of one Streptococcus OTU (Otu00020) and of 
the genus itself. From the advanced disease to the dysplasia/carcinoma groups we saw a rise in 
abundance of two diff erent Streptococcus OTUs (Otu00035 and Otu00061). Th e Prevotella OTU 
(Otu00128) had low mean abundance but a clear pattern, virtually disappearing in the dysplasia/
carcinoma group.
When the disease severity was measured with the ERC severity score as opposed to a 
categorical variable stratifi ed by disease stage, we detected two Streptococcus OTUs (Otu00020 
and Otu00061), each of them in common with one of the previous comparisons, and both 
positively correlated with increasing disease severity (Table 7, Figure 3b in Article III). 
Th e number of ERC examinations was included in the models and also investigated, since 
previous publications reported a potential impact of this procedure on the microbiota, especially 
on the streptococcal group. Th e results showed that one Streptococcus OTU (also detected in the 
dysplasia/carcinoma comparison, Otu00035) as well as the genus itself are positively correlated 
with the number of ERC examinations undergone by the patients (Table 7).
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Table 7. Diff erentially abundant (DESeq2: p < 0.05) taxa for bile data.
Family Genus OTU Mean Abundance
Log 2 Fold 
Change
SE of Log 2 
Fold Change p-value
Adjusted 
p-value
Controls  -> patients with early disease and no history of ERC examinations
Enterobacteriaceae unclassifi ed Otu00008 640 -4.65 1.27 2.42E-04 1.98E-02
Neisseriaceae Neisseria Otu00045 33 -3.18 0.94 7.14E-04 3.78E-02
Campylobacteraceae Campylobacter Otu00089 11 -2.79 0.77 2.80E-04 1.98E-02
Neisseriaceae unclassifi ed Otu00213 1 -5.01 1.17 1.78E-05 3.78E-03
Pasteurellaceae - - 14058 1.95 0.64 2.12E-03 3.25E-02
Staphylococcaceae - - 179 3.97 0.76 1.73E-07 7.95E-06
Xanthomonadaceae - - 11 3.58 1.11 1.20E-03 2.76E-02
Controls  -> patients with early disease
unclassifi ed 
Clostridiales unclassifi ed Otu00188 1 -6.10 1.41 1.43E-05 1.52E-03
Neisseriaceae unclassifi ed Otu00213 1 -4.91 1.10 7.64E-06 1.52E-03
Staphylococcaceae - - 179 4.18 0.76 4.09E-08 2.25E-06
Patients with early disease -> patients with advanced disease
Streptococcaceae Streptococcus Otu00020 728 4.94 0.83 3.22E-09 3.93E-07
Streptococcaceae Streptococcus - 9241 1.44 0.42 6.70E-04 4.94E-03
Patients with advanced disease -> patients with dysplasia/carcinoma
Streptococcaceae Streptococcus Otu00035 602 5.78 1.31 1.00E-05 7.10E-04
Streptococcaceae Streptococcus Otu00061 23 4.02 1.09 2.34E-04 8.25E-03
Prevotellaceae Prevotella Otu00128 6 -4.41 1.40 1.63E-03 3.15E-02
ERC severity score as a numerical variable
Streptococcaceae Streptococcus Otu00020 728 0.28 0.09 1.08E-03 4.35E-02
Streptococcaceae Streptococcus Otu00061 23 0.35 0.08 2.14E-05 1.74E-03
Number of ERC examinations (statistical model with disease severity as a grouped factor variable)
Streptococcaceae Streptococcus Otu00035 602 1.41 0.22 1.11E-10 2.54E-08
Streptococcaceae Streptococcus - 9241 0.39 0.10 1.25E-04 2.63E-03
Number of ERC examinations (statistical model with ERC severity score as a numerical variable)
Streptococcaceae Streptococcus Otu00035 606 0.94 0.23 5.43E-05 1.08E-03
Streptococcaceae Streptococcus - 9241 0.46 0.11 1.18E-05 4.96E-04
The two contrasts between the control group and the early disease groups contain all the original 
signi? cant results, for the reader’s convenience. The next ? ve comparisons contain only the results 
that passed assessment of robustness. Model variables common to all models: taxon ~ sequencing 
run + IBD status.
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5.  DISCUSSION
5.1.  Parkinson’s Disease
5.1.1.  Prevotellaceae and Biomarkers
Th e Prevotellaceae family contains four recognised genera, namely Prevotella, Aloprevotella, 
Hallella, and Paraprevotella (Rosenberg 2014). In our dataset, Prevotella constituted the vast 
majority of Prevotellaceae reads, and the genus was also statistically signifi cantly reduced in 
abundance in the PD group when the data was analysed at genus level (unpublished). Prevotella 
have also been found in reduced abundance in autistic children’s stool, while Enterobacteriaceae 
were increased (e.g. Kang et al. 2013, Krajmalnik-Brown et al. 2015). Prevotella are gram-negative 
bacteria that are associated with degradation of complex plant polysaccharides (indigestible by 
human enzymes) and mucin glycoproteins (Arumugam et al. 2011, Wu et al. 2011a, Chen et al. 
2007), the latter being secreted as a component of the gel-like mucus on the surface of the gut 
mucosa. Th is mucus serves as a barrier to pathogen breach of the epithelial layer and is part of 
the mucosal immune system (Murphy & Weaver 2016). Th ey are common members of the gut 
microbiota, and are the dominant component of one of the three originally proposed enterotypes 
(enterotype 2; Arumugam et al. 2011). Given our results, this leads to the prediction that PD 
prevalence should be lower in this enterotype’s population.
Although the genus Prevotella does not seem to be a major producer of short-chain fatty 
acids (SCFAs) in general nor of butyrate in particular (but see Chen et al. 2017 and references 
therein), there is evidence that higher Prevotella abundances are associated with communities 
with high production of various SCFAs due to diet-driven bacterial fermentation of complex 
plant-derived fi bers by various SCFAs-producing taxa (e.g. Ou et al. 2013, Chen et al. 2017). 
Th ese communities are also associated with high production of thiamine (vitamin B1) and 
folate (vitamin B9; Arumugam et al. 2011, Ou et al. 2013). Th ese vitamins, in turn, are found 
in reduced levels in PD subjects, and there is evidence that dietary supplements based on these 
have therapeutic eff ects in PD (dos Santos et al. 2009, Haghdoost-Yazdi et al. 2012, Luong & 
Nguyen 2013). SCFAs have an important role in host energy metabolism (den Besten et al. 
2013). Butyrate, for example, is the main energy source for the colonocytes that line the colon 
and has a role in preventing colon cancer (Vernocchi et al. 2016). It has also been shown to 
be an important mediator of colonic infl ammatory response by promoting the proliferation of 
regulatory T cells and increasing the production and circulation of anti-infl ammatory cytokines 
in the gut (Hoeppli et al. 2015). Th e latter is interesting given that pro-infl ammatory cytokines 
and oxidative stress have been causally linked to neuronal death (González et al. 2014, Kelly 
et al. 2014). Evidence has been shown that LPS compromises colon permeability, resulting in 
LPS leakage from the lumen to enteric neuronal tissues, triggering infl ammation and promoting 
neuronal alpha-synuclein overexpression and deposition (Kelly et al. 2014). Butyrate could thus 
have a role in counteracting LPS-driven gut infl ammation. Butyrate as well as butyrate-producing 
gut communities have also been linked, including experimentaly, to the re-establishment of 
compromised blood-brain barrier functions in germ-free mice (Al-Asmakh & Hedin 2015 and 
references therein). Pro-infl ammatory cytokines and active immune cells can access the brain 
especially when the blood-brain barrier is compromised, as can be the case in the context of 
neurodegenerative diseases, including PD (Houser et al. 2017 and references therein). Butyrate 
is also associated with increased gastrointestinal motility in rats, which is impaired in PD (Soret 
et al. 2010). Decreased levels of SCFAs were detected in children with Pervasive Developmental 
Disorder Not Otherwise Specifi ed (PDD-NOS) and children with Autism Spectrum Disorder 
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(ASD; De Angelis et al. 2013). Prevotella abundance, as well as the abundance of other fermenters 
like Coprococcus, were also found decreased in autistic children (Kang et al. 2013, Krajmalnik-
Brown et al. 2015). Interestingly, faecal concentrations of SCFAs have also been shown to be 
reduced in PD (Unger et al. 2016), and producers like Coprococcus, Roseburia, and the family 
Lachnospiraceae itself have been detected in lower abundances in PD (Keshavarzian et al. 2015, 
Hill-Burns et al. 2017). Prevotella has also been estimated to occur in lower abundances in other 
PD gut studies (Hasegawa et al. 2015, Keshavarzian et al. 2015, Unger et al. 2016).
On the other hand, Sampson et al. (2016), using GMO mice overexpressing alpha-synuclein, 
produced strong evidence that SCFAs produced by gut microbial communities are necessary to 
substantially develop motor defi cits, neuroinfl ammation, and amyloid pathology in PD mice 
models. Raising overexpressing mice gnotobiotically without gut bacteria substantially delayed 
the onset of motor symptoms and reduced gastrointestinal (GI) dysfunction (constipation) 
compared to overexpressing mice with gut microbiota. Overexpressing gnotobiotic mice 
also displayed substantially less alpha-synuclein pathology than overexpressing mice with gut 
microbiota. Young overexpressing mice treated with antibiotics display little motor dysfunction, 
similarly to overexpressing gnotobiotic mice, and improved GI function. Colonization of the 
gnotobiotic mice with bacteria from wild-type mice produced motor and GI dysfunction. Th e 
authors also observed lower faecal concentrations of SCFAs in gnotobiotic mice and antibiotic-
treated mice, as expected. Treating overexpressing gnotobiotic mice with butyrate, propionate, 
and acetate SCFAs increased microglia activation, neuroinfl ammation, and amyloid aggregation. 
SCFAs’ treatment also promoted motor defi cits and GI dysfunction when comparing to 
untreated gnotobiotic mice. Administering the anti-infl ammatory minocycline to the SCFA-fed 
overexpressing mice resulted in reduction of amyloid pathology and improved motor symptoms. 
Faecal transplants from human PD subjects (but not healthy subjects) to overexpressing mice 
exacerbated the motor symptoms. Th e alpha-synuclein overexpressing mice phenotype also 
aff ected the composition and structure of the gut microbiota aft er transplantation in a diff erent 
way from the wild-type mice, implying an interplay between the microbiota and the host’s 
genotype and phenotype. Overall, the study by Sampson et al. (2016) suggests that substantial 
levels of at least some SCFAs are linked with PD neuroinfl ammation and motor symptoms, in 
contrast with previous studies showing a reduction of SCFAs in PD (Unger et al. 2016) as well 
as lower levels of Prevotella (Hasegawa et al. 2015, Keshavarzian et al. 2015, Unger et al. 2016). 
However, lower levels of Prevotella alone can be compatible with overall high levels of SCFAs, 
since many other bacterial groups are involved in their production, including Clostridium 
cluster IV (Lopetuso et al. 2013, Riviere et al. 2016). We detected an increase in abundance in 
Clostridiales Incertae Sedis IV, which could be connected to production of SCFAs.
Decreased mucin production has been associated with increased colonic mucosal 
permeability, including in PD (Brown et al. 2011, Forsyth et al. 2011). Increased microbial-
induced butyrate production is associated with increased mucin production (Finnie et al. 1995, 
Wright et al. 2000, Burger-van Paassen et al. 2009). Prevotella, being mucin degraders (Wright 
et al. 2000), will tend to be associated with environments rich in mucin, and there is evidence 
that they are associated with bacterial communities rich in SCFAs’ production (e.g. Ou et al. 
2013, Chen et al. 2017), including butyrate, most probably as a consequence of increased fi ber 
consumption in the diet. Assuming these relationships are correct, lower Prevotella levels in PD 
correlate well with reduced mucin production and associated increase in mucosal permeability. 
Increased mucosal permeability can in turn lead to facilitated entry of toxins and/or pathogens 
into the host organism, which in turn could be aetiologically associated with PD (Niehaus & 
Lange 2003). Interestingly, alpha-synuclein was detected in elevated levels in colonic mucosal 
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staining associated with elevated gut permeability in PD (Forsyth et al. 2011), although this 
study was based on only 9 patients and 10 control subjects, and thus the putative increase in 
gut permeability in PD needs to be validated. Endotoxin (LPS) administration in mice models 
showed an increase in gut permeability and alpha-synuclein expression, leading to detection of 
alpha-synuclein accumulation in colonic myenteric neurons and in the brainstem, mimicking 
pre-motor pathology in humans (Kelly et al. 2014).
Finally, lower levels of ghrelin were found to correlate with lower abundance of Prevotellaceae 
and higher abundance of Lactobacillaceae in the colon of rat models subjected to diff erent 
regimens of nutrition and physical activity, showing that these aff ect microbial community 
composition (Queipo-Ortuno et al. 2013). Ghrelin is a gut hormone involved in regulation of 
nigrostriatal dopamine function, and may have a role in the prevention of neurodegeneration 
in PD (Bayliss et al. 2011). Impaired ghrelin secretion has also been shown to be present in PD 
subjects (Unger et al. 2011), and Prevotellaceae and Lactobacillaceae abundances varied in the 
same way as in our study (Queipo-Ortuno et al. 2013). However, in rats the increase in Prevotella 
abundance was associated with low calory intake, so it is not possible to rule out that these 
similarities are governed by a preference for certain diet regimens in PD. Feeding restriction 
(fasting) has also been previously associated with increased abundances of mucin-degraders, 
including Prevotella, which supports a diet-based explanation (Miller & Hoskins 1981, Deplancke 
et al. 2002). Unfortunately, a limitation of our studies is that it was not possible to assess diet 
data for analysis. To our knowledge, there is no general agreement regarding dietary preferences 
in PD, although some evidence suggests that PD patients preferentially adopt diets high in 
vegetable-derived fi bers and carbohydrates (Marczewska et al. 2006), which would suposedly 
promote high Prevotella levels (Wu et al. 2011a, Jeff ery & O’Toole 2013). If this is the case, diet 
alone cannot explain the overall lower relative abundance of gut Prevotella in PD. On the other 
hand, Hill-Burns et al. (2017) report that PD patients consume less fruits and vegetables, which 
supports Prevotella abundance being driven by diet preferences. Also, orthostatic hypotension, 
which aff ects 30-40% of PD patients, may produce dizziness, visual perturbations, and loss of 
consciousness, and in the more elderly patients it may tend to occur aft er feeding (Jost 2003, 
Iodice et al. 2011). Th is could conceivably lead to changes in diet as an attempt by the patient to 
ameliorate symptoms.
Overall, it is diffi  cult to envision a mechanism by which lower levels of Prevotella could be 
causally related to Parkinson’s disease. Note that although high abundances in our data are never 
found in PD unlike in controls, low levels are common to both groups, which argues against 
low Prevotella abundance in itself being causally related to PD. Regardless of the explanation for 
Prevotella diff erential abundance, it is important to view diseases and their causes in terms of 
the Suffi  cient-Component Cause Model proposed by Rothman (Rothman 1976, Rothman 2012). 
In this model, also known as the causal pie model, a given disease results from one or more 
suffi  cient causes. Th ese suffi  cient causes inevitably produce the disease. Any given suffi  cient cause 
is composed of component causes. Th ese component causes represent factors that, as a group, 
are all necessary and suffi  cient to cause a disease. Individually, they don’t cause the disease. Th e 
interesting part is that any particular disease can have more than one suffi  cient cause, representing 
diff erent “pathways” to the disease. As such, this model is of particular interest to microbiome-
based biomedical research, since it is unlikely that simplistic cause-eff ect explanations will 
elucidate diseases such as Parkinson’s or Alzheimer’s if indeed these are aetiologically related to 
the human microbiome. Th us, levels of Prevotella below a certain abundance threshold could 
perhaps be a necessary component cause of all suffi  cient cause models for PD (if more than one 
pathway exists) for reasons unknown at the moment, but it is not suffi  cient by itself. Alternatively, 
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low levels of Prevotella could be a component cause in only some suffi  cient cause pathways. Most 
probably, such complex diseases as PD involve microbial community composition shift s, with 
various microbial metabolic pathways involved, that somehow interact with the host’s immune 
system, neurological system, and general physiology. Nevertheless, it is necessary to fi rst elucidate 
if Prevotella abundances are a consequence of dietary eff ects in PD.
Other possible confounding factors besides diet warrant some discussion. Active or persistent 
Irritable Bowel Syndrome (IBS) and Infl ammatory Bowel Disease (IBD) were exclusion criteria 
in studies I and II (eTable 1 in supplementary material to Article I). Constipation is associated 
with PD and there is strong evidence for its eff ects on gut bacterial community composition (e.g. 
Zhu et al. 2014). Th e study by Zhu and colleagues detected lower levels of Prevotella in the gut of 
constipated patients, even though the number of subjects was low (8 constipated subjects vs. 14 
controls; 16S rRNA gene survey study). Th e cut-off  for positive diagnosis of constipation using 
the Wexner score is 15 (Agachan et al. 1996), which we felt was not adequate to meaningfully 
discriminate between constipated and non-constipated subjects, at least in our study groups. 
In fact, the highest scoring subject in our dataset (among both PD and control subjects) had 
a score of 14. Th erefore, the Wexner score seems to require a severe degree of constipation to 
allow diagnosis as such, making a prevalence analysis in our study diffi  cult. On the other hand, 
the Rome-III questionnaire (Longstreth et al. 2006), which was designed to evaluate functional 
bowel disorders, was deemed inferior for our purposes to the Wexner score, on the basis of the 
former not being validated through the use of objective physiological measurements (colonic 
transit time, anal manometry, cinedefecography, electromyography, etc). Th us, we opted to use 
Wexner as a graded severity score for constipation as opposed to a method for binary diagnosis 
of the same. Th is enabled us to use a severity scale during modelling to control for potential 
confounding eff ects. In our study, constipation didn’t seem to have any substantial eff ect on 
Prevotellaceae abundance (p = 0.74, Table 2 in Article I), with the only signifi cant eff ect being 
associated with study group.
Stool consistency has been linked with changes in microbial community composition 
(Vandeputte et al. 2016) making use of the Bristol Stool Scale (BSS) classifi cation system (Lewis & 
Heaton 1997) and 16S rRNA gene sequencing. Lower levels of Prevotella were linked with harder 
stool and slower transit times, while higher levels of Ruminococcaceae were associated with the 
same. As Vandeputte and colleagues noted, this could be a potential confounder in our study, 
since the microbial abundance diff erences observed could refl ect stool consistency diff erences in 
controls vs. PD patients that are related to higher prevalence/severity of constipation in PD and 
not specifi cally related to the disease. Th e authors propose that using the BSS classifi cation would 
help to disentangle eff ects from transit time and water activity from eff ects associated specifi cally 
with PD. However, it may be diffi  cult in practice to distinguish between both eff ects, given 
that the expected end results on the microbiota could very well be similar, that is, there could 
be a substantial degree of overlap between the BSS classifi cation and the measured severity of 
constipation with the Wexner score. Nevertheless, we think their concerns are valid, and transit 
time and water activity, as measured through the proxy of stool consistency, have some potential 
to confound results in stool-based studies.
Finally, regarding the potential eff ects of medications on Study I, we have included warfarin 
(an anticoagulant) and statins (lipid-lowering medications) in our models. Unfortunately (for 
us) only two PD subjects were completely free of any Parkinsonian medication, which meant 
that controlling for the eff ect of these drugs was not possible in an eff ective and satisfactory 
way, even though we detected a possible eff ect from COMT-inhibitors in the GLMs (Table 2 
in Article I). Hill-Burns et al. (2017) also detected a statistically signifi cant eff ect for COMT-
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inhibitors and anticholinergics. Importantly, COMT-inhibitors and anticholinergics can produce 
gastrointestinal side-eff ects. Th us, we are of the opinion that antiparkinsonian medication has the 
potential to be a confounder and should, as much as possible, be taken into account during the 
design of future studies, although this may be diffi  cult to achieve in practice given the “sample of 
convenience” nature of so many of these studies.
Since the publication of our article on human gut microbiota and PD in 2015, which was the 
fi rst study on the subject, a further four articles have been published at the time of this writing. 
Hasegawa et al. (2015) found that Lactobacillus were present in higher abundance in PD than 
in controls, which supports our fi ndings. Prevotella were estimated as being more abundant in 
controls than in PD, which also supports our fi ndings, but was not statistically signifi cant. Th ey 
were also the bacterial group that showed the greatest reduction in abundance in PD in their 
dataset. However, the study may have lacked statistical power (45 PD patients and 35 controls), 
and the controls were spouses, which may bias the estimations e.g. due to similar daily diets. Th e 
study used RT-PCR of 16S- and 23S rRNA as opposed to 16S rRNA gene amplicon sequencing. 
Keshavarzian et al. (2015) report that Prevotella abundances were reduced in sigmoid mucosal 
biopsies of PD as compared to controls (with less than half the mean PD abundance in controls), 
but again the result is not statistically signifi cant. Interestingly, the actual stool material showed 
virtually the same mean abundance in both PD subjects and controls. Th e number of samples 
was somewhat low, with 34 controls and 38 PD subjects. Unger et al. (2016) report that 
Prevotellaceae were also reduced in PD but not statistically signifi cant. Lactobacillaceae were 
reduced in PD, unlike our results. Th eir study is based on q-PCR and used 34 PD subjects and 
a corresponding number of age-matched controls, again on the low side. Finally, Hill-Burns et 
al. (2017) report that Lactobacillaceae were increased in abundance in PD, but don’t detect any 
variation in Prevotellaceae or Prevotella, except for a low abundance Prevotella OTU that was 
increased in PD. Ruminococcaceae were positively correlated with PD status. Th is family in our 
study (I) was found to be strongly associated only with Prevotellaceae abundance levels and not 
with disease status or any other clinical variable, suggesting that its increase in abundance in PD 
could be potentially explained either as occupation of available free niche space or due to direct, 
interspecifi c competition. Finally, their study was based on 197 cases and 130 controls. However, 
the study has one main issue: the stool samples were collected using sterile swabs (BD BBL™ 
CultureSwab™ Sterile, Media-free Swabs from Fisher Scientifi c), apparently without immersion 
in any kind of DNA stabilizing solution, and shipped to the destination laboratory through 
standard United States postal service at ambient temperature. Th ese swabs are apparently 
manufactured for taking samples and maintaining viability of cells for posterior culturing. 
However, their suitability to preserve complex community compositional relative abundances, 
especially for days, is doubtful. According to the authors, the postal service transit time was 
higher on average for the PD subjects’ samples (1-10 days, median 3 days, average 3.2 days) than 
for the controls’ (1-8 days, median 2 days, average 2.6 days). Th e authors attempt to control for 
this time discrepancy with statistical modelling, which is reasonable. However, no model-based 
adjustment is possible for the fact that all the stool samples have been in transit for days in the 
US postal service, at room temperature and apparently with no DNA stabilizing solution. Th us, 
the study’s results could be compromised to an undetermined extent.
It is interesting to note that all these studies, with the possible exception of Hill-Burns et al. 
(2017), support our results for a substantial Prevotellaceae/Prevotella abundance reduction in PD, 
although statistical signifi cance is never achieved even though the estimated eff ect sizes are large. 
Th is could occur due to a variety of reasons, including diff erent criteria for inclusion of cases 
and controls, diff erent data analysis methods, and use of diff erent clinical variables. Another 
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contributing factor could be that the number of biological samples included in these studies was 
relatively low except for Hill-Burns et al. (2017), and thus the high inter-individual variation in 
Prevotella abundance could result in a lack of statistical power to achieve statistical signifi cance. 
Nevertheless, the point estimates were consistently lower for Prevotellaceae/Prevotella in four 
out of fi ve studies, including ours (I), and the estimated eff ect sizes large and similar across the 
studies. Unfortunately, Hill-Burns et al. (2017) do not report the estimates for Prevotellaceae or 
Prevotella levels in their study, on the grounds that they were not statistically signifi cant.
Our results suggest that Prevotella (or Prevotellaceae) abundances could be used as a 
biomarker, regardless of the existence of an aetiological connection between Prevotella and PD. 
Th e ROC curve and logistic regression analyses point in this direction. It is clear from the fi rst 
of these analyses that Prevotellaceae abundance is a powerful discriminator for the identifi cation 
of positive PD cases, but is unable to distinguish the latter effi  ciently from the healthy subjects, 
leading to a high percentage of controls being erroneously identifi ed as cases along with the true 
positives. Th is could be due to the fact that, although high Prevotellaceae abundances are not 
present in PD, low Prevotellaceae abundances are common in both PD and healthy subjects. Th e 
addition of other variables reduces the amount of false positives substantially, but comes at the 
cost of increasing the number of PD cases erroneously identifi ed as negatives. Future studies, 
like the ones we are now working on, may potentially increase the sensitivity and specifi city of 
the models, and perhaps in the future it will be possible to use a combination of microbiome 
information from diff erent taxa together with clinical data to develop diagnostic tools for 
PD that could ideally be used before the onset of motor symptoms (Wu et al. 2011b). Th is is 
important, given that the reported accuracy of clinical diagnosis for PD varies between 26% and 
92%, improving with disease progression (Jankovic et al. 2000, Adler et al. 2014).
5.1.2.  PIGD and Enterobacteriaceae
Enterobacteriaceae abundance was reported as increased in PD by Unger et al. (2016). We did 
not fi nd this diff erential abundance in our data when contrasting PD patients with controls, but 
we did fi nd a diff erential abundance of Enterobacteriaceae between the Tremor Dominant (TD) 
and Postural Instability and Gait Diffi  culty (PIGD) groups, with the abundance being positively 
correlated with PIGD severity. In PD, patients with non-tremor dominant phenotype show faster 
disease progression and more severe alpha-synuclein pathology in the colonic enteric nervous 
system (Lebouvier et al. 2010, Marras & Lang 2013).
Intestinal permeability, for which evidence exists for an increase in PD, has been positively 
correlated with intestinal mucosal staining for E. coli and alpha-synuclein (Forsyth et al. 2011), 
although the sample size in this study is small. LBP levels (LPS-binding protein) were lower in 
PD subjects, with low levels of LBP having been shown previously to support a role for endotoxin 
in promoting infl ammatory pathways and cytokine production (Forsyth et al. 2011). However, 
this study didn’t detect an actual increase in serum LPS levels in PD. Nevertheless, Escherichia/
Shigella belong to the Enterobactereaceae family, which interestingly was found to be positively 
correlated with the PIGD phenotype in our study.
As mentioned previously, reduced levels of SCFAs are present in PD, and low levels of 
butyrate and other SCFAs seem to be associated with Prevotella-poor gut microbiomes. High 
fi ber-content diets lead to high amounts of SCFAs, which lower the pH of the colon, since the 
host releases bicarbonate during absorption of SCFAs. Th is lower pH aff ects the abundance and 
composition of the colonic bacteria, which in turn aff ects the production of SCFAs, potentially 
leading to even lower SCFAs’ levels (den Besten et al. 2013). Concentration of SCFAs decreases 
Discussion
34
from the upper parts of the colon to the rectum, thereby increasing the pH in the same direction 
(Jacobs & Lupton 1986, Cummings et al. 1987, Ward & Coates 1987, Annison et al. 2003). 
An increase in pH in these distal parts of the colon, especially if promoted by abnormally low 
amounts of SCFAs, can reduce the abundance of butyrate-producing bacteria (or even almost 
eradicate them) and increase the abundance of Enterobacteriaceae (Prohaszka et al. 1990, 
Cherrington et al. 1991, Walker et al. 2005, Duncan et al. 2009, den Besten et al. 2013).
However, in what way Enterobacteriaceae could potentially infl uence motor symptoms in 
PD remains unknown, although endotoxin-induced cascades or neurotransmitters of bacterial 
origin are a possibility (Niehaus & Lange 2003), as discussed in section 1.2. On the other hand, it 
is possible that the Enterobacteriaceae abundance increase in PIGD is simply refl ecting increased 
pH levels in the colon. However, to our knowledge, no study has shown higher pH levels in 
PIGD patients compared to TD patients.
5.1.3.  Oral and Nasal Bacteria in Parkinson’s Disease
Th e results for alpha and beta diversity with the oral and nasal datasets are supported by previous 
studies that show higher diversity levels in bacterial oral communities when compared to nasal 
communities, as well as community compositions that are more similar to each other according to 
anatomical area than according to specifi c individuals (Bassis et al. 2014). Th e general community 
composition of our oral dataset is also in accordance with previously published studies, showing 
a dominance of Streptococcus and a wide distribution of opportunistic pathogens, including in 
healthy individuals (Bik et al. 2010, Palmer 2014). 
Prevotella and Prevotellaceae were found increased in abundance in the oral samples of 
PD patients when compared to controls. Th e genus includes well known opportunistic oral 
pathogens (Tanaka et al. 2008). Th is led us to speculate that this increase could be related to 
hygiene practices. Lower frequencies of tooth brushing, less frequent visits for medical dental 
care, as well as higher prevalence of caries, periodontal disease, and tooth loss have all been 
reported in PD (Muller et al. 2011), but a more recent study reported effi  cient dental health 
care among PD patients based on self-assessment (Barbe et al. 2017), leaving the question 
open. Curiously, our data showed that several of the taxa associated with opportunistic oral 
pathogenicity were actually reduced in PD (seven out of fourteen OTUs, two out of fi ve genera, 
and one out of fi ve families, all potentially being or including pathogenic opportunistic taxa), 
which argues against hygiene as the sole explanation for these diff erential abundances. Th e other 
possible explanation, alone or in tandem with hygiene practices, is dietary preference. Some 
studies suggest that e.g. Prevotella grows preferentially on vegetable fi bers and carbohydrates, and 
that PD patients consume more vegetable proteins and carbohydrates (Marczewska et al. 2006, 
Wu et al. 2011a, Jeff ery & O’Toole 2013), thus potentially explaining the observed abundance 
diff erence for this genus in particular. On the other hand, one study reports that diet doesn’t 
signifi cantly aff ect oral bacterial communities (De Filippis et al. 2014). Again, the evidence is 
inconclusive. All the remaining taxa that were not associated with opportunistic pathogens were 
found decreased in abundance in PD, with the exception of Moryella and Erysipelotrichaceae, but 
further investigation suggests that these two taxa may be false positives resulting from chance 
eff ects.
Finally, we found evidence for an increase in putative oral pathogens in male subjects, 
regardless of PD status. Th is result is supported by studies showing worse oral hygiene practices 
among the male population in general (Helldán & Helakorpi 2014). Overall, the existence of 
diff erences in oral microbial composition between PD patients and controls suggests that 
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these could be potentially exploited as biomarkers, regardless of causation, but that potential is 
nevertheless very limited.
Th e nasal dataset shows a community composition similar to that reported in previous 
studies (Bassis et al. 2014, Biswas et al. 2015). No alpha or beta diversity diff erences were found 
between controls and PD patients. As for diff erentially abundant taxa between these two groups, 
the genus Marmoricola, decreased in PD, has only been isolated from environmental sources, 
suggesting it may be a lab contaminant (Kim et al. 2015). Flavobacteriaceae were estimated as 
being reduced in PD, and this family contains genera known to be human pathogens. However, 
no OTUs or genera belonging to this family were detected as diff erentially abundant. Also, 
its reduced abundance in PD argues against an aetiological connection with PD. Finally, a 
Staphylococcus OTU was found increased in abundance in PD. Oligotyping produced three 
oligotypes, one resembling S. epidermis, another S. aureus, and an unresolved Staphylococcus. All 
had similar relative abundances between the PD and control groups, producing no statistically 
signifi cant hits. In conclusion, our study suggests that nasal microbial communities are not 
related to Parkinson’s disease and off er no biomarker potential.
5.2.  Primary Sclerosing Cholangi? s
We investigated alpha diversity of the bile communities in control, early disease, advanced 
disease, and dysplagia/carcinoma groups. Analysis of the samples suggests that diversity is similar 
in the control group and the early disease stage subjects, and that it then drops progressively 
throughout the advanced and dysplasia/carcinoma stages, with the latter also showing the 
sharpest diversity decline. Th ese results are in line with previously reported fi ndings for PSC 
in the literature (Rossen et al. 2015, Kummen et al. 2016, Sabino et al. 2016), although those 
studies are based on stool samples as opposed to bile samples. However, given that the source 
of bile microbiota is thought to originate in the duodenum, these parallel fi ndings are worth 
considering.
 
 
5.2.1.  No Ae? ological Role for Microbiota?
Except for the Neisseriaceae OTU (Otu00213), none of the reported taxa, including those 
detected at family level analysis, showed credible patterns under visual inspection, suggesting 
that they could be false positives. Furthermore, the Enterobacteriaceae, Neisseria, Campylobacter, 
Neisseriaceae, and Clostridiales OTUs (Otu0008, Otu00045, Otu00089, Otu00213, and Otu00188, 
respectively) were all found reduced in the early disease stage group, which argues against an 
etiological role for these groups in PSC. In fact, all OTUs detected were reduced in abundance 
in the early disease stage, with only families showing a putative increase. Also, except for the 
Enterobacteriaceae OTU, all OTUs show very low to extremely low mean abundances.
Th e families Pasteurellaceae, Staphylococcaceae, and Xanthomonadaceae contain known 
human pathogens, but as a group all are quite diverse. Th us, given that detection in all cases 
occurred only at family level and with no corresponding genera or OTUs detected, the results 
do not convincingly suggest an infectious role for specifi c organisms in these families in the 
initiation of PSC, although the family as a whole could still conceivably infl uence naïve PSC 
development. Furthermore, Xanthomonadaceae are present in very low mean abundance. Th e 
only family detected in common in both early disease models was Staphylococcaceae, members 
of which (e.g. Staphylococcus aureus) have been previously detected, e.g. in PSC cultures (Olsson 
et al. 1998) and in sequencing-based studies (Hiramatsu et al. 2000).
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Although the statistical signifi cance of the above results is suspicious, it would be premature 
to fully disregard them as false positives, and therefore it is possible that some results may be 
validated in future studies. Nevertheless, as a whole, our fi ndings fail to provide convincing 
evidence for the direct involvement of bile microbiota in the aetiology of PSC.
5.2.2.  Streptococcus and Disease Progression
Both Streptococcus as a genus as well as one OTU belonging to this taxon (Otu00020) were 
found to increase in abundance from early disease to advanced disease stage. From the latter 
to the dysplasia/carcinoma stage, two diff erent Streptococcus OTUs are also seen to increase 
in abundance (Otu00035 and Otu00061). Th e same pattern was seen when the analysis was 
performed with the ERC severity score as a numerical variable, with the abundance of two 
Streptococcus OTUs (Otu00020 and Otu00061, each in common with one of the two previous 
comparisons) being positively correlated with disease severity. Overall, the results show a 
generalised streptococcal increase matching disease progression. Notice that this eff ect is 
detected even though the number of ERC examinations were used for eff ect adjustment in the 
models.
Assessment of the number of ERC examinations in two separate models, in turn, also 
resulted in the detection of an increase in abundance of the Streptococcus genus and one OTU 
belonging to this group (Otu00035, the same in both models), which is in line with previous 
studies linking nosocomial infections due to cannulation during ERC, with alpha-haemolytic 
streptococci being the main culprits (Olsson et al. 1998). Hiramatsu et al. (2000) detected 
Streptococcus milleri in one out of fi ve PSC patients in gallbladder bile cultures and in sequenced 
material from the same individual.
However, notice that Streptococcus is also present in our control group in similar abundances 
to the early disease subjects. Th is could be a consequence of our control subjects maybe not being 
fully representative of a “healthy” bile, since all had medical indication to undergo ERC due to 
inconclusive fi ndings during magnetic resonance cholangiopancreatography (MRCP) of the bile 
ducts or due to elevation of serum alkaline phosphatase (ALP) of unknown origin. Th e ERC, and 
in most cases liver histology, excluded the presence of PSC. If the bile of the control subjects is 
not representative of “normal” bile, then that could also explain why no clear diff erences were 
found between controls and naïve PSC subjects. However, this control group is by necessity a 
sample of convenience, since it would be diffi  cult (and perhaps unethical) to obtain bile samples 
through ERC from volunteers with no reason to undergo such an intrusive procedure. At 
present, there is no agreement on what microbial communities in “normal” bile duct-derived 
bile, if any, should look like (Verdier et al. 2015). Overall, our results support the hypothesis that 
streptococcal infection occurs due to ECR cannulation and is not related to the aetiology of PSC, 
but also that the nosocomial infection thus developed does seem to have a role in the progressive 
development of the disease.
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6.  CONCLUSIONS
Th e abundances of Prevotellaceae and its genus Prevotella in the gut (I) were found to be negatively 
correlated with PD. Given the very high within-group variation in the abundance of these 
taxonomic groups it is doubtful that this factor alone would lead to PD development. However, 
the groups’ potential as biomarkers for PD is promising, especially combined with other taxa and 
clinical data, given the need to evaluate the risk of development of PD before amyloid pathology 
inception. When PD is traditionally diagnosed, it is already too late to apply treatments that could 
potentially avoid or signifi cantly delay neuronal death. Study limitations regarding confounding 
by factors like diet and medication remain, but nevertheless the reduced-Prevotella hypothesis 
generated by Study I has subsequently been given support by three independent studies on the 
microbiome in PD at the time of this writing, with a fourth study regrettably not reporting the 
estimated eff ect size and direction for Prevotella or Prevotellaceae abundance.
Enterobacteriaceae were found to be positively correlated with motor phenotype, specifi cally 
postural instability and gait diffi  culty, suggesting the possibility that this group could somehow 
aff ect motor control. Th e mechanisms, however, remain speculative and were not targeted in our 
studies. No diff erences in alpha diversity were found between PD and control groups, suggesting 
that species richness and evenness are similar among the two populations. On the other hand, 
beta diversity analysis showed diff erences at family-level, suggesting that there are signifi cant 
compositional diff erences in the gut bacterial communities between the two populations.
As for the oral and nasal microbiota (II), the results for alpha and beta diversity are supported 
by previous studies that show higher diversity levels in oral communities than nasal communities, 
as well as community compositions that are more similar to each other according to anatomical 
area than to specifi c individuals. Th e oral communities showed a dominance of Streptococcus 
and a wide distribution of opportunistic pathogens, including in healthy individuals. Curiously, 
our data suggested that many of the taxa associated with opportunistic pathogens were actually 
reduced in PD. Overall, the evidence is stronger for diff erences between PD and controls in the 
oral area, but no overall clear pattern emerges. Our study suggests that oral communities show 
little potential for use as biomarkers.
Regarding PSC (III), we found no convincing evidence for a role of bile microbiota in 
the aetiology of the disease. Diff erential abundance analysis between controls and naïve PSC 
patients resulted in the detection of some taxa showing problematic features that suggest they 
may be false positives, and most were reduced in abundance. Nevertheless, future studies may 
eventually validate some of those results. More robust were the fi ndings for disease progression, 
suggesting a clear increase in streptococcal abundances as disease severity increases and fi nally 
reaches neoplasia. Our results also support previous studies that suggest that members of the 
Streptococcus genus are associated with nosocomial infections due to cannulation of the bile 
ducts during ERC. Alpha diversity analysis suggested that diversity decreases as the disease 
increases in severity, with a sharp diversity drop in the neoplasia group. Limitations regarding 
the characterization of “healthy bile” and the use of proper controls remain, both in our study 
and for studies on PSC in general.
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